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I. Summary 
 
Mammalian Target of Rapamycin (mTOR) signaling is a crucial regulator of 
cell growth and metabolism.  The highly conserved serine/threonine protein 
kinase mTOR is activated by growth factors, such as insulin and insulin-like 
growth factor 1 (IGF-1), nutrients, and it is sensitive to the cellular energy 
state.  mTOR forms two structurally and functionally distinct multi-protein 
complexes, termed mTOR complex 1 (mTORC1) and mTORC2, through 
which it regulates distinct downstream processes, such as protein synthesis, 
lipogenesis, nucleotide biosynthesis, glucose metabolism, autophagy and cell 
survival.  Deregulation of mTOR signaling is often associated with metabolic 
diseases, such as diabetes, obesity and cancer.  While the role of mTOR 
signaling in regulating growth and metabolism in single cells is quite well 
understood, the non-cell autonomous effects of mTOR signaling are still only 
poorly characterized. 
In order to better understand the role of tissue-specific mTOR signaling 
in organismal energetics, we investigated the role of mTORC1 signaling in 
hypothalamic orexigenic Agrp neurons and its influence on systemic energy 
homeostasis and feeding behavior.  We therefore generated Agrp neuron-
specific raptor knockout (Agrp-raptor KO) mice, which display inactive 
mTORC1 signaling in Agrp neurons.  Agrp-raptor KO mice exhibited a 
decrease in the circadian expression of orexigenic neuropeptides, but they did 
not show any defects in energy homeostasis and feeding behavior when fed 
either a standard diet or a high fat diet.  Thus, our findings demonstrate that 
mTORC1 signaling in Agrp neurons is dispensable for the regulation of 
systemic energy homeostasis and feeding behavior. 
In the second part of this thesis, we investigated the role of mTORC2 
signaling in adipose tissue with particular focus on how adipose mTORC2 
affects non-shivering thermogenesis (NST) and cold-induced glucose uptake.  
We found that mTORC2 signaling was induced in brown adipocytes by β-
adrenergic stimulation via cAMP, Epac1 and PI3K.  Furthermore, mTORC2 
signaling in adipose tissue was required for temperature homeostasis, since 
mice lacking mTORC2 signaling in mature adipocytes (adipose tissue specific 
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rictor knockout (AdRiKO) mice) were hypothermic and sensitive to cold stress.  
While lipid store mobilization and induction of oxidative metabolism and 
mitochondrial uncoupling were not impaired in AdRiKO mice, inactivation of 
mTORC2 signaling in adipose tissue resulted in a significant impairment in 
cold-induced glucose uptake and glycolysis in brown adipose tissue (BAT).  
Interestingly, restoration of glucose metabolism in BAT via introduction of a 
constitutively active form of Akt2 or via over-expression of hexokinase II 
increased body temperature and improved cold tolerance of AdRiKO mice.  
Hence, our findings identify mTORC2 in BAT as a novel regulator of systemic 
energy homeostasis upon NST by affecting cold-induced glucose uptake and 
glycolysis. 
Taken together, this thesis provides new insights into the non-cell 
autonomous functions of mTORC1 in Agrp neurons and mTORC2 in BAT.  
These findings could facilitate the development of novel drugs to treat 
metabolic disorders, such as obesity and diabetes.	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II. Abbreviations 
 
4E-BP eukaryotic translation initiation factor (eIF4E) binding protein 
AdRaKO adipose tissue-specific raptor knockout 
AdRiKO adipose tissue-specific rictor knockout 
Agrp Agouti-related peptide 
Agrp-raptor 
KO 
Agrp neuron-specific raptor knockout 
Agrp-rictor 
KO 
Agrp neuron-specific rictor knockout 
AMPK AMP-activated protein kinase 
ARC Arcuate nucleus 
AS160 Akt substrate of 160kDa 
ATG13 autophagy-related 13 
ATG14 autophagy-related 14 
ATGL adipose tissue triglyceride (TG) lipase 
BAD bcl-2 associated death promoter 
BAT brown adipose tissue 
Bim bcl-2-like 11 
BNIP3 bcl-2/adenovirus E1B 19kDa interacting protein 
brite brown in white 
C/EBPα CCAAT/enhancer binding protein α 
C/EBPβ CCAAT/enhancer binding protein β 
C/EBPγ CCAAT/enhancer binding protein γ 
CAD Carbamoyl phosphate synthethase 2, aspartate 
transcarbamoylase, and dihydroorotase 
cAMP cyclic AMP 
CBP80 nuclear cap-binding protein subunit 1 
ChIP chromatin immunoprecipitation 
CNS central nervous system 
DIO diet-induced obesity 
Dio2 type II iodothyronine deiodinase 
DMH dorsomedial hypothalamic nucleus 
ECAR extracellular acidification rate 
Ednra endothelin receptor type A 
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eEF2K eukaryotic elongation factor 2 kinase 
eIF4B eukaryotic translation initiation factor 4B 
eIF4E eukaryotic translation initiation factor 4E 
eIF4G eukaryotic translation initiation factor 4G 
ETC electron transport chain 
FAs fatty acids 
FAT focal adhesion kinase targeting 
FATC FRAP, ATP, TRAP C-terminal 
FGF-21 fibroblast growth factor 21 
FKBP FK506 binding protein of 12kDa 
FOX forkhead box 
FOXO O-subfamily of the FOX proteins 
FRB FKBP12-rapamycin binding 
G6P glucose-6-phosphate 
GFP green fluorescent protein 
GLUT1 glucose transporter 1 
GLUT4 glucose transporter 4 
GSK3 glycogen synthase kinase 3 
HFD high fat diet 
HSL hormone sensitive lipase 
IGF-1 insulin-like growth factor 1 
IKKα IκB kinase α 
IR insulin receptor 
IRS-1 insulin receptor substrate 1 
JAKs janus kinases 
L-raptor KO liver-specific raptor knockout 
L-TSC1 KO liver-specific TSC1 knockout 
LHA lateral hypothalamic area 
LiRiKO liver-specific rictor knockout 
LR leptin receptor 
MAG monoglyceride lipase 
MC-3R melanocortin 3 receptor 
MC-4R melanocortin 4 receptor 
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MCP-1 monocyte-chemoattractant protein 1 
mLST8 mammalian lethal with sec-13 protein 
mSIN1 mammalian stress-activated map kinase-interacting protein 1 
mTOR mammalian target of rapamycin 
mTORC1 mammalian target of rapamycin complex 1 
mTORC2 mammalian target of rapamycin complex 2 
Myf5 myogenic factor 5 
NE norepinephrine 
NF-κB nuclear factor κ-light-chain-enhancer of activated B cells 
NPY neuropeptide Y 
NST non-shivering thermogenesis 
OCR oxygen consumption rate 
PDK1 phosphoinositide-dependent kinase 1 
PGC-1α peroxisome proliferator-activated receptor γ coactivator 1α 
PI3K phosphatidylinositol 3-kinase 
PIKK phosphatidylinositol 3-kinase-related kinase 
PKA protein kinase A 
PKC protein kinase C 
POMC pro-opiomelanocortin 
POMC-
rictor KO 
POMC neuron-specific rictor knockout 
POMC-
TSC1 KO 
POMC neuron-specific TSC1 knockout 
PPARα peroxisome proliferator-activated receptor α 
PPARγ peroxisome proliferator-activated receptor γ 
PPP pentose phosphate pathway 
PRDM16 PRD1-BF-1-RIZ1 homologous domain-containing protein-16 
Psat phosphoserine aminotransferase 
PTEN phosphatase and tensin homolog  
PVN paraventricular nucleus 
RAG RAS-related GTP-binding protein 
RAmKO raptor muscle knockout 
raptor regulatory associated protein of mTOR 
Rheb Ras homolog enriched in brain 
rictor rapamycin insensitive companion of mTOR 
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RImKO rictor muscle knockout 
S6K S6 kinase 
SGK serum- and glucocorticoid-induced protein kinase 1 
SKAR Aly/REF-like substrate 
SREBP sterol regulatory element-binding protein 
STAT3 signal transducer and activator of transcription 3 
sWAT subcutaneous white adipose tissue 
TBC1D7 TBC1 domain family member 7 
TBP TATA box binding protein 
TFEB transcription factor EB 
TGs triglycerides 
TNF-α tumor necrosis factor α 
TOR target of rapamycin 
TSC1 tuberous sclerosis complex 1 
TSC2 tuberous sclerosis complex 2 
TSCmKO TSC1 mucle knockout 
UCP1 uncoupling protein 1 
ULK1 UNC-51-like kinase 1 
VO2 oxygen consumption 
WAT white adipose tissue 
ZT Zeitgeber 
α-MSH α-melanocyte stimulating hormone 
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1.   Introduction 
  
1.1  The TOR signaling pathway 
 
 TOR – a key regulator of cell growth and metabolism 
 Target of Rapamycin (TOR) is a highly conserved serine/threonine 
kinase that is a key regulator of cell growth and metabolism.  TOR has 
been identified in all eukaryotes examined to date, including worms, 
flies, mammals, and plants.  TOR was originally discovered in yeast 
through isolation of yeast mutants, which were resistant to the growth-
inhibitory effects of the macrolide rapamycin (Heitman et al. 1991, 
Kunz et al. 1993).  Before the discovery of TOR, cell growth was 
thought to be a passive, non-regulated process that occurred when 
nutrients were abundant.  However, since the discovery of TOR, it has 
become evident that cell growth is a tightly regulated process that 
involves a complicated signaling network in order to adapt growth and 
metabolism to environmental conditions.  TOR is a nutrient and energy 
sensor and forms the central node of a complex signaling network that 
senses the energy status of a cell or an organism and adapts growth 
and metabolism accordingly (Wullschleger et al. 2006, Loewith and 
Hall 2011, Laplante and Sabatini 2012, Dibble and Manning 2013, 
Shimobayashi and Hall 2014). 
 
Structure and complex formation of TOR 
 TOR is a member of the phosphatidylinositol 3-kinase (PI3K)-related 
kinase (PIKK) family.  While PI3Ks are lipid kinases, to date no lipid 
kinase activity has been observed for any member of the PIKK family 
(Keith and Schreiber 1995).  TOR and related PIKK members are 
thus exclusively protein kinases. 
 The mammalian TOR (mTOR) protein consists of 2549 amino 
acids and contains a number of distinct and highly conserved domains 
(Figure 1).  The N-terminal part of TOR consists of tandem HEAT 
repeats that are predicted to form a superhelical structure, which 
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enables interaction of TOR with other proteins (Perry and Kleckner 
2003).  The C-terminal part of TOR contains a focal adhesion kinase 
targeting (FAT) domain and an FK506 binding protein of 12kDa 
(FKBP12)-rapamycin binding (FRB) domain. Rapamycin forms a 
complex with FKBP12, which binds to the FRB domain and inhibits 
TOR activity (Brown et al. 1994, Sabatini et al. 1994, Stan et al. 
1994).   The FRB domain is followed by the highly conserved kinase 
domain and a FRAP, ATP, TRAP C-terminal (FATC) domain.  All 
members of the PIKK family possess a FAT and FATC domain.  While 
the exact role of this domain is 
yet unknown, it is speculated 
that it might be involved in the 
regulation of kinase activity 
(Sekulic et al. 2000).	  	  
 
 TOR forms two 
structurally and functionally 
distinct complexes, which are 
highly conserved between 
eukaryotes.  In mammals, 
these two complexes are 
called mammalian TOR Complex 1 (mTORC1) and mTORC2.  
mTORC1 consists of mTOR, mammalian lethal with sec-13 protein 
(mLST8), and regulatory associated protein of mTOR (raptor) (Figure 
2).  mTORC2 contains mTOR, mLST8, mammalian stress-activated 
map kinase-interacting protein 1 (mSIN1), and rapamycin insensitive 
companion of mTOR (rictor) (Wullschleger et al. 2006, Loewith and 
Hall 2011, Laplante and Sabatini 2012, Dibble and Manning 2013, 
Shimobayashi and Hall 2014) (Figure 2).  Importantly, while 
mTORC1 is sensitive to rapamycin, mTORC2 is rapamycin-insensitive 
since the FRB domain is masked when mTOR is in complex with the 
proteins forming the mTORC2 complex (Jacinto et al. 2004, 
Sarbassov et al. 2004).  In particular, in yeast it has suggested that 
the C-terminal part of the rictor ortholog Avo3 might be involved in 
Figure 1. Structure of TOR (Benjamin et 
al. 2011).  See text for details. 	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masking the FRB domain (Gaubitz et al. 2015). Due to the rapamycin 
insensitivity of mTORC2 many other mTOR inhibitors have been 
developed, such as Torin1, Torin2, PP242, INK128, and AZD-8055, to 
name a few.  These inhibitors block mTOR kinase activity by acting as 
ATP-competitive mTOR inhibitors and thus block both mTORC1 and 
mTORC2 activity (Benjamin et al. 2011, Schenone et al. 2011).  
However, to date no mTORC2-specific inhibitor is available. 
 
 
 
Upstream of mTORC1 and mTORC2 
mTORC1 and mTORC2 are activated by overlapping as well as distinct 
upstream signals and regulate different sets of downstream effector 
pathways (Figure 2).	   
 
Upstream of mTORC1 
mTORC1 is activated by growth factors, such as insulin or insulin-like 
growth factor 1 (IGF-1), amino acids and cellular energy (Dibble and 
Manning 2013). 
Growth factors.  Growth factors activate mTORC1 via the 
PI3K/Phosphoinositide-dependent kinase 1 (PDK1)/Akt signaling 
pathway (Figure 3).  Once growth factors, such as insulin or IGF-1 
bind to the insulin or IGF-1 receptor, this leads to phosphorylation and 
Figure 2. Overview on mTORC1 and mTORC2 signaling.  See text for details. 
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activation of Akt via PI3K-mediated activation PDK1 (Taniguchi et al. 
2006, Laviola et al. 2007).  Akt then inactivates the Tuberous 
Sclerosis Complex 1 (TSC1)-TSC2-TBC1 domain family member 7 
(TBC1D7) complex by phosphorylating TSC2 at multiple sites.  This 
activates mTORC1, since the TSC1-TSC2-TBC1D7 complex is a 
negative regulator of the small GTPase Ras homolog enriched in brain 
(Rheb) (Inoki et al. 2002).  Active Rheb in turn binds and activates 
mTOR via a still unknown mechanism (Long et al. 2005). 
Amino acids.  Besides growth factors, mTORC1 is also 
activated by amino acids (Figure 3).  Amino acids activate mTORC1 in 
a RAS-related GTP-binding protein (RAG)-dependent manner (Kim et 
al. 2008, Sancak et al. 2008, Sancak et al. 2010).  There are four 
different RAG proteins, RAGA, RAGB, RAGC, and RAGD and they 
belong to a family of small GTPases.  RAGs form heterodimers, where 
RAGA or RAGB forms a heterodimer with RAGC or RAGD. Upon 
amino acid stimulation, the RAG heterodimer converts to its active 
state via a still not fully understood mechanism.  In this activated state 
RAGA or RAGB is loaded with GTP and RAGC or RAGD is loaded with 
GDP.  Activation of the RAG heterodimer leads to the translocation of 
mTORC1 to the lysosome where it is activated by Rheb, which 
mediates the growth factor stimulated activation of mTORC1.  Hence, 
for full activation of mTORC1 both amino acids and growth factors are 
required. 
Cellular energy.  Cellular energy status is the third major input 
that regulates mTORC1 activity (Figure 3).  When intracellular energy 
levels drop, a high intracellular AMP/ATP ratio activates AMP-activated 
protein kinase (AMPK). AMPK phosphorylates TSC2, thereby 
stimulating the GAP activity of the TSC1-TSC2-TBC1D7 complex 
towards Rheb, resulting in inhibition of mTORC1 (Corradetti et al. 
2004, Inoki et al. 2006).  Additionally, AMPK also phosphorylates 
raptor, leading to binding of raptor to 14-3-3 scaffolding proteins and 
thereby inhibition of mTORC1 (Gwinn et al. 2008).  Consequently, 
when intracellular ATP levels are high, AMPK becomes inactive and 
this releases the inhibition of mTORC1. 
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Upstream of mTORC2 
In comparison to the upstream regulation of mTORC1, less is known 
about upstream regulators of mTORC2.  To date the only known 
upstream regulators of mTORC2 are growth factors (Frias et al. 2006, 
Yang et al. 2006, Garcia-Martinez and Alessi 2008).  Growth factors 
activate mTORC2 via a different mechanism compared to the growth 
factor-mediated activation of mTORC1.  Activation of mTORC2 by 
growth factors is induced by PI3K-dependent association of mTORC2 
with ribosomes (Zinzalla et al. 2011) (Figure 3).  However, how PI3K 
mediates association of mTORC2 with ribosomes still has to be 
elucidated. 
       
 Figure 3. Upstream of mTOR signaling (Shimobayashi and Hall 2014).  See text 
for details. 
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Downstream of mTORC1 and mTORC2 
mTORC1 and mTORC2 phosphorylate a distinct set of downstream 
targets through which they promote anabolic processes, such as 
protein synthesis, ribosome biogenesis, nucleotide biosynthesis,  
lipogenesis, cell survival and nutrient uptake, while they inhibit 
catabolic processes, such as autophagy (Dibble and Manning 2013, 
Shimobayashi and Hall 2014) (Figure 2).   
 
Downstream of mTORC1 
The best characterized downstream targets of mTORC1 are ribosomal 
protein S6 kinase (S6K), eukaryotic translation initiation factor 4E 
(eIF4E) binding proteins (4E-BPs), and the autophagy activating kinase 
UNC-51-like kinase 1 (ULK1) (Ma and Blenis 2009).  In this section 
the main downstream processes regulated by mTORC1 will be 
discussed. 
Protein synthesis.  mTORC1 regulates protein synthesis 
mainly via S6K and 4E-BPs.  Upon phosphorylation by mTORC1, 4E-
BPs dissociate from eIF4E.  This allows binding of eIF4G to eIF4E at 
the 5’-end of mRNAs, thereby promoting cap-dependent translation 
initiation.  S6K in turn regulates protein synthesis through 
phosphorylation and activation of its downstream target S6, which 
stimulates expression of mRNAs involved in ribosome biogenesis 
(Chauvin et al. 2014).  Moreover, S6K also phosphorylates a number 
of proteins involved in translation or mRNA processing, such as eIF4B, 
eukaryotic elongation factor 2 kinase (eEF2K), programmed cell death 
4 (PDCD4), nuclear cap-binding protein subunit 1 (CBP80), and S6K1 
Aly/REF-like substrate (SKAR) (Wilson et al. 2000, Wang et al. 2001, 
Raught et al. 2004, Richardson et al. 2004, Peschiaroli et al. 2006, 
Shahbazian et al. 2006).  Hence, mTORC1 affects protein synthesis at 
multiple levels by regulating ribosome biogenesis protein expression, 
translation initiation, and mRNA processing. 
Lipogenesis.  Besides its role in stimulating protein synthesis, 
S6K is also involved in mediating the stimulatory effects of mTORC1 
on lipogenesis (Duvel et al. 2010).  Transcription of lipogenic genes is 
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regulated by sterol regulatory element-binding protein (SREBP) 
transcription factors.  mTORC1 stimulates lipogenesis by promoting 
SREBP maturation in an S6K-dependent fashion (Duvel et al. 2010).  
Moreover, mTORC1 directly phosphorylates and inhibits phosphatidate 
phosphatase LPIN1 (Lipin-1), which is a negative regulator of SREBP 
(Peterson et al. 2011). 
Nucleotide biosynthesis.  mTORC1 stimulates de novo 
nucleotide biosynthesis by promoting transcription of pentose 
phosphate pathway (PPP) genes (Duvel et al. 2010).  This increases 
the amount of intracellular ribose, which can serve as building blocks 
for purines and pyrimidines.  Importantly, PPP gene transcription is 
dependent on SREBP.  Thus, mTORC1 regulates PPP gene 
transcription in a similar fashion as lipogenic gene transcription (Duvel 
et al. 2010).  Additionally, mTORC1 stimulates CAD protein activity 
through S6K-mediated phosphorylation of CAD (Ben-Sahra et al. 
2013, Robitaille et al. 2013).  CAD catalyzes the three initial rate-
limiting steps of de novo pyrimidine synthesis, since it encodes three 
distinct enzymatic activities (carbamoyl phosphate synthethase 2, 
aspartate transcrabamoylase, and dihydroorotase). 
Autophagy.  Autophagy is a process where cellular 
components are degraded to remove damaged proteins and organelles 
and to provide substrates for energy production under nutrient-poor 
conditions.  mTORC1 inhibits autophagy by directly phosphorylating 
several proteins involved in regulating autophagy.  For example, 
mTORC1 phosphorylates ULK1, autophagy-related 13 (ATG13), and 
ATG14, leading to inhibition of autophagosome formation (Ganley et 
al. 2009, Hosokawa et al. 2009, Jung et al. 2009, Kim et al. 2011).  
Moreover, mTORC1 also prevents transcription of lysosome 
biogenesis genes by phosphorylating transcription factor EB (TFEB). 
TFEB regulates transcription of genes involved in lysosome biogenesis 
and upon phosphorylation; TFEB is retained in the cytoplasm.  This in 
turn blocks transcription of lysosome biogenesis genes when mTORC1 
is active (Roczniak-Ferguson et al. 2012). 
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Downstream of mTORC2 
mTORC2 downstream targets are members of the AGC kinase family, 
such as Akt, serum/glucocorticoid regulated kinase (SGK) and protein 
kinase C (PKC) through which mTORC2 regulates lipogenesis, glucose 
uptake, glycolysis, and cell survival (Sarbassov et al. 2004, Hresko 
and Mueckler 2005, Sarbassov et al. 2005, Facchinetti et al. 2008, 
Garcia-Martinez and Alessi 2008, Ikenoue et al. 2008, Jacinto and 
Lorberg 2008). 
 Lipogenesis.  mTORC2 is a crucial regulator of lipogenesis in 
the liver.  Hepatic mTORC2 promotes lipogenesis by stimulating 
SREBP1 expression and maturation in an Akt-dependent manner 
(Hagiwara et al. 2012, Yuan et al. 2012).  Hence, both mTORC1 and 
mTORC2 are important for the regulation of hepatic lipid homeostasis 
(see below for more details on the regulation of hepatic lipid 
metabolism by mTORC1 and mTORC2). 
 Glucose uptake and glycolysis.  Upon insulin stimulation, 
glucose is taken up by extra-hepatic organs, such as skeletal muscle or 
adipose tissue and then degraded via glycolysis or stored in the form of 
glycogen.  mTORC2 is a key regulator of glucose homeostasis by 
regulating insulin-stimulated glucose uptake, glycolysis and 
glycogenesis (Kumar et al. 2008, Hagiwara et al. 2012).  Insulin-
stimulated glucose uptake is dependent on Akt-mediated 
phosphorylation of Akt substrate of 160kDa (AS160), which results in 
translocation of glucose transporter 4 (GLUT4) from internal vesicles to 
the plasma membrane (Kane et al. 2002).  Upon insulin stimulation, 
mTORC2 is required for activation of Akt and subsequent translocation 
of GLUT4 to the plasma membrane.  Glycolytic flux is dependent on 
the rate of glucose uptake and on the activity of hexokinases, which 
phosphorylate glucose to generate glucose-6-phosphate (G6P).  
mTORC2 regulates glycolytic flux via Akt by promoting insulin-
stimulated glucose uptake and by stimulating the expression of the 
liver-specific hexokinase 4 (also termed glucokinase) (Kumar et al. 
2008, Hagiwara et al. 2012).  Finally, hepatic mTORC2 promotes 
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glycogenesis by inhibiting glycogen synthase kinase 3 (GSK3) in an 
Akt-dependent manner (Hagiwara et al. 2012). 
 Cell survival.  mTORC2 signaling plays a critical role in the 
promotion of cell survival via its downstream target Akt (Manning and 
Cantley 2007).  Akt phosphorylates and inhibits the pro-apoptotic 
protein bcl-2-associated death promoter (BAD), which blocks apoptosis 
(Zha et al. 1996, Datta et al. 1997).  Akt also phosphorylates IκB 
kinase α (IKKα), resulting in the activation of nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB) signaling and the 
expression of pro-survival genes (Ozes et al. 1999, Dan et al. 2008).  
Akt is a negative regulator of the O-subfamily of the forkhead box 
(FOX) transcription factor family (FOXO).  Upon phosphorylation by 
Akt, FOXOs translocate from the nucleus to the cytoplasm, resulting in 
reduced transcription of FOXO-target genes (Matsuzaki et al. 2003).  
FOXOs are important transcription factors involved in the regulation of 
apoptotic gene expression by inducing transcription of pro-apoptotic 
genes, such as bcl-2-like 11 (Bim) and bcl-2/adenovirus E1B 19kDa 
interacting protein 3 (BNIP3) (Dijkers et al. 2000, Dijkers et al. 2002, 
Stahl et al. 2002, Gilley et al. 2003).  Hence, mTORC2 promotes cell 
survival by inhibiting the expression of genes involved in apoptosis via 
Akt-dependent inhibition of FOXO. 
 
1.2 mTOR in metabolic organs 
Due to the central role of mTOR in cell growth and metabolism, 
deregulation of the mTOR signaling pathway is often associated with 
the development of metabolic disorders, such as obesity, diabetes and 
cancer (Dazert and Hall 2011, Laplante and Sabatini 2012).  Hence, 
mTOR signaling in individual metabolic organs has a major impact on 
whole-body metabolism and energy homeostasis (Table 1).  To study 
in vivo functions of mTOR signaling in metabolic tissues, a large 
number of genetically modified mouse models with tissue-specific 
deletions of mTOR signaling components have been generated and 
characterized.  In this section the phenotype of these mouse models 
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will be discussed and the role of mTORC1 and mTORC2 in liver, 
skeletal muscle, hypothalamus and adipose tissue will be described.  
An important point to consider when characterizing mice with chronic 
alterations of mTORC1 signaling is the negative feedback loop formed 
via S6K phosphorylation and inactivation of insulin receptor substrate 1 
(IRS-1) (Shah et al. 2004, Um et al. 2004, Ueno et al. 2005).  Thus, 
induction of this feedback loop prevents activation of mTORC1 and 
mTORC2.  Hence, in a state where mTORC1 signaling is chronically 
activated or inhibited this negative feedback loop causes alterations in 
mTORC2 and Akt signaling and could account for some of the 
observed phenotypes in these mouse models.   
 
 mTOR in liver 
The liver is crucial for systemic metabolism by regulating glucose and 
lipid homeostasis, protein synthesis, detoxification of compounds, and 
hormone production.  Analysis of genetically modified mice with liver-
specific deletions of mTOR signaling components have revealed that 
the mTOR signaling pathway is important for liver function (Table 1). 
 Hepatic mTORC1 is involved in the regulation of systemic 
glucose homeostasis (Table 1).  This has become evident since liver-
specific TSC1 knockout (L-TSC1-KO) mice with chronic mTORC1 
activation in the liver are glucose intolerant (Sengupta et al. 2010, 
Kenerson et al. 2011, Yecies et al. 2011).  Hyperactivation of 
mTORC1 in the liver of L-TSC1-KO mice inhibits Akt signaling through 
constitutive activation of the negative feedback loop from S6K to IRS-1 
(Shah et al. 2004, Um et al. 2004, Ueno et al. 2005). Consequently, 
hepatic glucose uptake and glycolytic flux is reduced, resulting in 
impaired glucose clearance from the blood.  In contrast, liver-specific 
raptor KO (L-raptor-KO) mice display increased hepatic Akt signaling, 
resulting in enhanced hepatic glucose uptake and improved systemic 
glucose tolerance (Peterson et al. 2011, Umemura et al. 2014).  
Similar to mTORC1, hepatic mTORC2 also regulates systemic glucose 
homeostasis (Table 1).  In analogy with L-TSC1-KO mice, liver-specific 
rictor KO (LiRiKO) mice display impaired hepatic Akt signaling.  This 
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results in a diabetic phenotype due to decreased insulin-stimulated 
hepatic glucose uptake and glycolysis (Hagiwara et al. 2012). 
 Apart from its role in glucose metabolism, the liver is the major 
site of lipogenesis (Eberle et al. 2004).  As mentioned earlier, in vitro 
studies have shown that mTORC1 stimulates lipogenesis through 
induction of SREBP-1 expression, maturation and activation 
(Porstmann et al. 2008, Duvel et al. 2010, Li et al. 2010, Peterson et 
al. 2011).  Surprisingly, L-TSC1-KO mice display a decreased SREBP-
1 activity and reduced lipogenesis despite hyper-activation of mTORC1 
(Sengupta et al. 2010, Kenerson et al. 2011, Yecies et al. 2011, 
Cornu et al. 2014).  Thus, in vivo hyper-activation of mTORC1 is not 
sufficient to induce hepatic de novo lipogenesis.  Similar to the 
regulation of glucose metabolism, there are also similarities between L-
TSC1-KO mice and LiRiKO mice in regard to regulation of hepatic 
lipogenesis.  Hepatic mTORC2 activates Akt and thereby stimulates 
SREBP-1 expression and maturation, which in turn activates 
lipogenesis (Hagiwara et al. 2012).  LiRiKO mice are thus 
hypolipidemic with a decrease in hepatic and circulating triglycerides 
due to impaired Akt-stimulated hepatic lipogenesis.  
 The liver is essential for the maintenance of whole-body energy 
homeostasis, since it converts excess nutrients, such as carbohydrates 
or lipids, to glycogen and triglycerides and stores them for periods of 
nutrient scarcity.  During nutrient deprivation, the liver prevents 
systemic hypoglycemia through production of glucose via breakdown of 
glycogen (glycogenolysis) or via de novo synthesis of glucose 
(gluconeogenesis).  Recently, it has become evident that hepatic 
mTORC1 signaling is crucial for the maintenance of whole-body energy 
homeostasis during nutrient deprivation (Cornu et al. 2014).  Chronic 
activation of mTORC1 in the liver upon fasting causes metabolic stress, 
which activates expression of the stress hormone fibroblast growth 
factor 21 (FGF-21). FGF-21 decreases locomotor activity and body 
temperature by acting on the central nervous system (Bookout et al. 
2013) (Table 1).  Hence, proper regulation of hepatic mTORC1 activity 
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with regard to the energy status of an organism is crucial for 
maintenance of whole-body energy homeostasis. 
 
 mTOR in skeletal muscle 
Skeletal muscle is the largest organ in the body, and modulation of 
skeletal muscle metabolism has substantial impact on whole-body 
energy homeostasis (Egan and Zierath 2013).   Characterization of 
mice with skeletal muscle-specific alterations in mTOR signaling has 
revealed that skeletal muscle mTOR signaling plays an important role 
in the regulation of systemic glucose metabolism, energy homeostasis, 
oxidative metabolism and skeletal muscle mass (Table 1). 
Upon insulin stimulation, skeletal muscle accounts for the 
majority of glucose removal from the circulation (Yang 2014).  Hence, 
skeletal muscle is crucial for the regulation of systemic glucose 
homeostasis.  Skeletal muscle mTORC1 and mTORC2 are both 
involved in regulating systemic glucose homeostasis (Table 1).  
Skeletal muscle-specific rictor KO (RImKO) mice display decreased Akt 
signaling in skeletal muscle, resulting in impaired insulin-stimulated 
glucose uptake and glycolysis in skeletal muscle and systemic glucose 
intolerance (Kumar et al. 2008) (Table 1).  Hence, skeletal muscle 
mTORC2 mediates insulin-induced glucose uptake and glycolysis.  In 
contrast to this, skeletal muscle-specific raptor KO (RAmKO) mice 
display hyper-activated Akt in skeletal muscle due to lack of the 
negative feedback loop from S6K to IRS-1 (Bentzinger et al. 2008).  
This results in increased glycogen accumulation in the muscles of 
RAmKO mice.  However, despite enhanced Akt signaling in skeletal 
muscle, RAmKO mice are slightly glucose intolerant (Bentzinger et al. 
2008) (Table 1).  Thus, inactivation of skeletal muscle mTORC1 exerts 
a negative effect on systemic glucose homeostasis, which cannot be 
reversed by hyper-activation of Akt. 
 Since mTORC1 is an important regulator of protein synthesis, 
skeletal muscle mTORC1 signaling is crucial for maintenance of 
skeletal muscle mass.  In line with this, RAmKO mice display a 
progressive loss of muscle mass due to reduced rates of protein 
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synthesis (Bentzinger et al. 2008) (Table 1).  Surprisingly, skeletal 
muscle-specific TSC1 KO (TSCmKO) mice are also dystrophic despite 
hyper-activation of mTORC1-stimulated protein synthesis (Castets et 
al. 2013) (Table 1).  The dystrophy in TSCmKO mice is due to 
impaired autophagy, which leads to muscle wasting due to 
accumulation of damaged proteins.  Hence, mTORC1 activity in 
skeletal muscle must be tightly regulated, since both too much and too 
little mTORC1 activity leads to a deregulation of muscle homeostasis. 
Apart from regulation of muscle mass and glucose homeostasis, 
mTORC1 signaling is also an important regulator of skeletal muscle 
oxidative function.  Consequently, skeletal muscle of RAmKO mice 
displays a strong reduction in oxidative capacity (Bentzinger et al. 
2008) (Table 1). In contrast, hyperactivation of mTORC1 signaling in 
skeletal muscle in TSCmKO mice enhances oxidative activity, 
suggesting that mTORC1 stimulates oxidative function in skeletal 
muscle (Bentzinger et al. 2013) (Table 1). 
Finally, skeletal muscle mTORC1 signaling is important for the 
regulation of whole-body energy homeostasis.  Both RAmKO and 
TSCmKO mice display a progressive loss of adipose tissue mass due 
to enhanced energy expenditure (Bentzinger et al. 2008, Castets et 
al. 2013) (Table 1).  Hence, similar to the effects on muscle mass, tight 
regulation of mTORC1 activity in skeletal muscle is crucial for the 
regulation of systemic energy homeostasis. 
Dissertation - mTOR signaling in organismal energetics 
	   28  
Table 1. Effects of mTOR signaling in different organs on whole body metabolism 
(Albert and Hall 2014).  See text for details. 
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 mTOR in hypothalamus 
The central nervous system (CNS) and energy homeostasis 
The CNS plays an essential role in the regulation of systemic energy 
homeostasis (Luquet and Magnan 2009).  The CNS senses the 
metabolic state of an organism by receiving humoral and neuronal 
signals from peripheral organs.  Integration of these signals leads to 
adaptation of energy expenditure and feeding behavior in order to 
maintain systemic energy homeostasis.  The importance of the CNS as 
a central regulator of energy homeostasis is underscored by the fact 
that individuals suffering from metabolic disorders often display a 
dysfunction in CNS-mediated control of energy homeostasis (Velloso 
et al. 2009, Williams 2012).  The brain region that is of particular 
importance for the regulation of systemic energy homeostasis is the 
hypothalamus (Wilding 2002).  The hypothalamus is localized above 
the brain stem and below the thalamus, forming the ventral part of the 
diencephalon.  The hypothalamus contains several distinct regions that 
are involved in the regulation of feeding and energy expenditure 
(Figure 4).  These are the arcuate nucleus (ARC), the ventromedial 
nucleus of hypothalamus (VMH), the paraventricular nucleus (PVN), 
the dorsomedial hypothalamic nucleus (DMH), and the lateral 
hypothalamic area (LHA).  Due to the proximity of the ARC to the 
median eminence it is viewed as a central integrator of hormonal 
signals originating from the periphery.  At the median eminence-ARC 
contact site, the blood brain barrier is semi-permeable to allow entry of 
peripheral peptides, such as insulin and leptin, into the CNS.  Neurons 
within the ARC are therefore directly exposed to peripheral hormones 
(Levin et al. 2011).  ARC neurons are connected to other 
hypothalamic areas, such as the PVN, the DMH, and the LHA. These 
hypothalamic areas further integrate the signals received from the ARC 
in order to regulate feeding behavior and energy expenditure. 
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The role of the ARC in feeding and energy homeostasis 
The ARC contains two distinct neuronal populations, which either 
stimulate appetite or cause cessation of feeding.  Appetite stimulatory 
neurons express orexigenic neuropeptides, such as neuropeptide Y 
(NPY) and Agouti-related peptide (Agrp), while appetite inhibitory 
neurons express the anorexigenic neuropeptide pro-opiomelanocortin 
(POMC) (Cone et al. 2001, Neary et al. 2004, Arora and Anubhuti 
2006).  Receptors for NPY are G-protein coupled receptors, which are 
termed Y1, Y2, Y4, Y5, and Y6 (Wahlestedt and Reis 1993, Gehlert 
2004).  Agrp on the other hand is a potent antagonist for melanocortin 
3 and 4 receptors (MC-3R and MC-4R) (Yang 2014).  POMC is 
cleaved by endopeptidases to generate α-melanocyte stimulating 
Figure 4. Schematic representation of the hypothalamic nuclei and other higher 
brain regions (Yeo and Heisler 2012).  See text for details. 
1. Introduction 
	   31 
hormone (α-MSH), which is an agonist for MC-3R and MC-4R 
(Pritchard et al. 2002).  Neurons within the PVN, DMH, and LHA 
express NPY receptors, MC-3R and MC-4R and their activity is 
therefore directly modulated by Agrp, NPY and POMC to regulate 
feeding behavior (Xia and Wikberg 1997, Fetissov et al. 2004, Siljee 
et al. 2013) (Figure 4). 
The most important peripheral hormones that regulate feeding 
behavior and energy homeostasis are leptin, insulin, and ghrelin.  
Leptin is secreted from adipose tissue and its circulating levels are 
proportional to adipose tissue mass (Considine et al. 1996).  Insulin is 
secreted from pancreatic β-cells in response to increased post-prandial 
blood glucose levels (Komatsu et al. 2013).  Importantly, Agrp/NPY 
and POMC neurons express the insulin receptor (IR) and the leptin 
receptor (LR), which enables these neurons to respond to these 
peripheral hormones (Havrankova et al. 1978, Meister 2000).  Since 
insulin and leptin levels rise under nutrient rich conditions, both 
hormones induce an appetite-inhibitory, i.e. anorexigenic, response in 
the ARC.  Leptin and insulin stimulate anorexigenic POMC neurons 
and inhibit orexigenic Agrp/NPY neurons, resulting in increased energy 
expenditure and cessation of feeding (Varela and Horvath 2012).  On 
a molecular level, leptin and insulin stimulate POMC and inhibit Agrp 
and NPY expression via the signal transducer and activator of 
transcription 3 (STAT3) and the PI3K/Akt/ FOXO1 signaling pathways 
(Figure 5).  When leptin binds to its receptor, Janus kinases (JAKs) are 
recruited to the leptin receptor, leading to its phosphorylation and 
activation.  This allows binding of STAT3 to the LR.  JAKs 
subsequently phosphorylate STAT3, which results in STAT3 
dimerization and translocation to the nucleus.  In the nucleus, the 
STAT3 dimer stimulates POMC transcription in POMC neurons and 
inhibits Agrp and NPY transcription in Agrp/NPY neurons (Mesaros et 
al. 2008, Ernst et al. 2009).  Insulin binds to the IR and activates 
PI3K/Akt signaling.  Akt is a negative regulator for FOXO1, causing its 
nuclear exclusion upon its phosphorylation (Matsuzaki et al. 2003).  In 
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Agrp/NPY neurons, FOXO1 stimulates Agrp and NPY expression, 
while it inhibits POMC expression in POMC neurons (Kitamura et al. 
2006, Plum et al. 2009).  Hence, upon insulin stimulation FOXO1 is 
phosphorylated and therefore excluded from the nucleus, which results 
in a decrease in Agrp and NPY expression and an increase in POMC 
expression. 
In contrast to these anorexigenic peptides, ghrelin induces an 
orexigenic response.  Ghrelin is mainly synthesized in endocrine cells 
of the gastric mucosa and it acts via stimulation of Agrp and NPY 
production.  Ghrelin also antagonizes the inhibitory effect of leptin on 
Agrp/NPY neurons (Greenman et al. 2004).  Hence, ghrelin causes an 
induction of feeding and an increase in energy expenditure.  However, 
the molecular signaling pathways mediating the effects of ghrelin on 
Agrp and NPY expression are still poorly understood. 
 
 
 A potential role for mTOR signaling in the hypothalamus 
As mentioned earlier, mTOR is a nutrient and energy sensor and 
therefore a crucial regulator of metabolism and energy homeostasis.  In 
particular, insulin is an important growth factor which regulates both 
mTORC1 and mTORC2 activity.  Since, Agrp/NPY and POMC 
expression is also regulated by insulin it has been hypothesized that 
Figure 5. Insulin and leptin regulate Agrp and POMC expression (Plum et al. 2006).  See 
text for details. 
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mTOR signaling plays an important role in the hypothalamic regulation 
of feeding behavior and energy homeostasis.  Indeed, mTORC1 
activity in the ARC is low in fasted animals and high during feeding, 
suggesting that hypothalamic mTORC1 activity is sensitive to the 
feeding state (Cota et al. 2006).  Moreover, mTORC1 activity is 
increased specifically in POMC but not Agrp/NPY neurons in aged 
mice, leading to POMC neuronal dysfunction and thereby contributing 
to aging-induced obesity (Yang et al. 2006).  Importantly, POMC-
specific TSC1 KO (POMC-TSC1 KO) mice with chronic mTORC1 
hyper-activation in POMC neurons, display hyperphagia-induced 
obesity due to decreased POMC expression (Mori et al. 2009) (Table 
1).  Interestingly, POMC-specific rictor KO (POMC-rictor KO) mice, 
which display inactive mTORC2 signaling in POMC neurons, also 
develop an obese and hyperphagic phenotype (Kocalis et al. 2014) 
(Table 1).  Thus, the hyperphagic phenotype of POMC-rictor KO and 
POMC-TSC1 KO mice could be due to impaired Akt signaling.  As 
mentioned in the previous section, Akt is a negative regulator of 
FOXO1.  In POMC-rictor KO and POMC-TSC1 KO mice Akt signaling 
is impaired, which leads to nuclear localization and activation of 
FOXO1.  Activated FOXO1 represses POMC expression, resulting in 
decreased POMC levels and hyperphagia.  Surprisingly, inactivation of 
mTORC2 specifically in Agrp neurons does not result in any alterations 
in feeding behavior or energy homeostasis (Kocalis et al. 2014). 
Hence, mTORC2 signaling is a crucial regulator of POMC neuronal 
function, which affects both feeding behavior and systemic energy 
homeostasis, while it is dispensable for Agrp neuronal function. 
 
mTOR in adipose tissue 
Adipose tissue is a heterogeneous organ consisting of adipocytes, 
preadipocytes, fibroblasts, endothelial cells, and immune cells, such as 
macrophages, B- and T-cells.  There are three different types of 
adipose tissue: white adipose tissue (WAT), brown adipose tissue 
(BAT), and beige adipose tissue, also termed “brown-in-white” (brite) 
adipose tissue (Figure 6).  White, brown and beige adipocytes arise 
Dissertation - mTOR signaling in organismal energetics 
	   34 
from different progenitors and they have distinct functions.  However, 
all types of adipose tissue have a crucial role in the regulation of whole-
body energy homeostasis. 
 
Origin and function of WAT 
White adipocytes arise from preadipocytes, which originate from 
mesenchymal stem cells that have undergone an early commitment to 
the adipocyte lineage (Rosen and MacDougald 2006) (Figure 6), a 
process that is not yet fully elucidated.  Subsequently, upon terminal 
differentiation, white preadipocytes acquire the functional properties of 
mature white adipocytes.  This terminal differentiation process is tightly 
regulated by the expression of key transcription factors involved in 
adipogenesis, such as CCAAT/enhancer binding protein α, β, and 
δ (C/EBPα, β, and δ) and peroxisome proliferator-activated receptor γ 
(PPARγ) (Rosen and MacDougald 2006). 
Energy storage and release.  The main function of WAT is to 
store energy and excess nutrients in the form of triglycerides (TGs) 
when nutrient availability is high.  White adipocytes are characterized 
by a single large lipid droplet where TGs are stored, which can account 
for over 90% of the cell volume (Haugen and Drevon 2007) (Figure 
Figure 6. Origin of brown, white and beige adipocytes (Rosen and Spiegelman 
2014).  See text for details. 
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6).  TGs that are stored in WAT are mainly derived from dietary fats, 
and only a small fraction is generated by de novo lipogenesis in 
adipocytes.  Dietary fat is digested in the stomach and small intestine 
to yield fatty acids (FAs).   In enterocytes of the intestine FAs are re-
synthesized to TGs, packaged into chylomicrons, and released into the 
circulation.  Chylomicrons are lipoproteins containing TGs, cholesterol 
and vitamins, specialized in transporting lipids in the circulation.  FAs 
are released from chylomicrons by lipoprotein lipases that are 
expressed in endothelial cells of the capillaries within WAT depots.  
The released FAs then diffuse into adipocytes where they are re-
synthetized to TGs by esterification with glycerol 3-phosphate and 
stored within lipid droplets.  Additionally, excess carbohydrates can 
also be converted to TGs via de novo lipogenesis in both liver and 
WAT and stored within lipid droplets (Penicaud et al. 2000). 
Stored TGs can be mobilized from lipid droplets by lipases, such 
as hormone sensitive lipase (HSL), adipose tissue TG lipase (ATGL) 
and monoglyceride lipase (MAG) in a process termed lipolysis 
(Duncan et al. 2007).  Lipolysis is induced in WAT upon β-adrenergic 
stimulation, and involves activation protein kinase A (PKA), which 
phosphorylates and stimulates HSL activity.  The FAs generated 
through lipolysis are released into the blood stream and transported to 
other organs.  Hence, lipolysis in WAT is crucial to provide energy for 
other organs in times of low nutrient availability, such as during 
starvation or when systemic energy demand is increased, for example 
during intense exercise or upon cold exposure.  
Endocrine function.  WAT exerts many of its effects on 
systemic energy homeostasis and metabolism via secretion of a variety 
of adipose-derived hormones, termed adipokines, which act on other 
organs (Trayhurn and Beattie 2001, Trayhurn and Wood 2004).  
Adipokines include growth- and angiogenic factors, chemokines, 
cytokines, adhesion molecules and hormones (Figure 7).  Through 
these adipokines, adipose tissue is able to affect a variety of systemic 
processes ranging from angiogenesis, immune response, glucose 
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homeostasis and feeding behavior (Trayhurn and Wood 2004).  
Importantly, deregulation of WAT function, for example in an obese or 
diabetic state, leads to aberrant adipokine secretion, thereby having a 
major impact on systemic metabolic homeostasis. 
    
 
Regulation of inflammation.  Recently, it has become evident 
that WAT plays an important role in immune function, thereby 
contributing to the regulation of both local and systemic inflammation 
(Rosen and Spiegelman 2014).  This has become apparent since 
WAT actively secretes cytokines, such as tumor necrosis factor α 
(TNF-α) or interleukin 6 (IL-6) (Hotamisligil et al. 1993).  Under obese 
conditions, the secretion of these pro-inflammatory cytokines is 
enhanced, which contributes to diet-induced adipose tissue and 
systemic insulin resistance (Hotamisligil et al. 1993).  Interestingly, 
more than 60% of all cells within a WAT depot can be of immune origin 
(Kanneganti and Dixit 2012), suggesting that the majority of cytokines 
secreted from WAT are secreted by immune cells and not by 
adipocytes (Weisberg et al. 2003, Xu et al. 2003).  Macrophages play 
a particularly important role in WAT immune function.  There are two 
different types of macrophages, which are termed M1 (classically 
Figure 7. Adipokines secreted by WAT (Lago et al. 2007).  
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activated) and M2 (alternatively activated) (Mills 2012).  M2 
macrophages display an anti-inflammatory phenotype and they are the 
dominating macrophage-population in WAT under lean conditions.  
Under obese conditions, the number of pro-inflammatory M1 
macrophages strongly increases, resulting in an elevated secretion of 
pro-inflammatory cytokines and impaired insulin sensitivity (Lumeng et 
al. 2007, Lumeng et al. 2007).  In line with this, overexpression of 
monocyte-chemoattractant protein 1 (MCP-1) leads to macrophage-
infiltration and insulin resistance while its inhibition ameliorates insulin 
resistance in obese mice (Kamei et al. 2006, Kanda et al. 2006).  In 
contrast to this, TNF-α KO mice that lack an immune response, display 
a worsened insulin resistance upon diet-induced obesity (DIO) 
(Wernstedt Asterholm et al. 2014).  Hence, the precise role of 
adipose tissue inflammation in obesity is not yet completely 
understood.  However, the above-mentioned observation suggests that 
adipose tissue inflammation is not necessarily only detrimental and can 
also exert positive effects on metabolic health in obese conditions. 
 
Origin and function of BAT   
BAT develops during embryogenesis prior to the formation of other 
adipose tissue depots.  Most brown adipocytes arise from myogenic 
factor 5 (Myf5) and paired box protein 7 (Pax7) double-positive 
progenitor cells, which also give rise to skeletal muscle cells (Seale et 
al. 2008) (Figure 6).  Hence, brown adipocytes are more closely 
related to skeletal muscle myocytes than to white adipocytes.  
Commitment of Myf5 positive progenitors to the brown adipocyte 
lineage is mediated by PRD1-BF-1-RIZ1 homologous domain-
containing protein-16 (PRDM16) (Seale et al. 2007, Seale et al. 2008).  
PRDM16 directly binds to the DNA and induces expression of BAT-
characteristic genes, such as PPARγ coactivator 1α (PGC-1α), 
uncoupling protein 1 (UCP1), and type II iodothyronine deiodinase 
(Dio2).  Importantly, PRDM16 also inhibits expression of several white 
adipocyte specific genes, such as resistin, angiotensinogen, endothelin 
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receptor type A (Ednra) and phosphoserine aminotransferase (Psat) 
(Kajimura et al. 2008). 
 
Non-shivering thermogenesis (NST) and energy dissipation.  
In contrast to the energy storing properties of WAT, BAT is mainly 
involved in temperature homeostasis and NST by dissipating energy in 
the form of heat. NST allows mammals to maintain stable body 
temperature in a cold environment.  Upon cold exposure, 
norepinephrine (NE) is released from sympathetic nerves and binds to 
β3-adrenergic receptors on brown adipocytes to induced NST.  β3-
adrenergic receptor stimulation induces cAMP production and 
subsequent activation of PKA.  PKA signaling then stimulates lipid 
mobilization, β-oxidation and mitochondrial uncoupling (Cannon and 
Nedergaard 2004) (Figure 8).   
 
 
 
 
 
 
 
 
 
 
Thus, brown adipocytes are characterized by possessing a large 
number of mitochondria and many small lipid droplets that can be 
easily mobilized to generate substrates for mitochondrial uncoupling 
(Figure 6).  Mitochondrial uncoupling is achieved by activating UCP1, 
which is a member of the mitochondrial carrier protein family and 
specifically expressed in brown adipocytes.  It is a transmembrane 
protein found in the mitochondria and its function is to dissipate the 
proton gradient across the inner mitochondrial membrane generated by 
the electron transport chain (ETC).  This uncouples the proton flux into 
Figure 8. β-adrenergic 
stimulation induces non-
shivering thermogenesis 
in BAT (Cannon and 
Nedergaard 2004).  See 
text for details. 
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the mitochondria from ATP production, resulting in heat generation 
(Klaus et al. 1991, Busiello et al. 2015).  When NST is not active, 
UCP1 is inhibited by cytosolic nucleotides, such as GDP, GTP, ADP 
and ATP (Nicholls 1974).  However, upon β-adrenergic stimulation, 
UCP1 activity is stimulated by FAs via a still not fully understood 
mechanism (Rial et al. 1983).  Either FAs act as direct cofactors for 
UCP1 or they increase UCP1 activity by preventing binding of inhibitory 
cytosolic nucleotides.  Consequently, release of FAs is essential for 
NST and defects in FA uptake, FA transport or lipolysis result in 
impaired UCP1 activity and reduced heat generation upon cold stress 
(Haemmerle et al. 2006, Wu et al. 2006, Vergnes et al. 2011).  
Additionally, β-adrenergic stimulation induces UCP1 transcription upon 
cold stress, resulting in increased UCP1 protein levels and thereby an 
enhanced thermogenic capacity.  Due to the ability of BAT to efficiently 
burn energy, activation of NST and subsequent energy dissipation has 
been proposed as a strategy to induce weight loss in obese patients 
(Clapham and Arch 2011).  Hence, a large amount of work has gone 
into identifying novel regulators of NST.  Table 2 summarizes the most 
important factors in BAT that can affect thermogenesis.  Importantly, 
most of the identified proteins modulate expression of thermogenic 
genes, such as UCP1, thereby regulating energy dissipation. 
 
  
Table 2. Mouse models with increased NST (Harms and Seale 2013). 
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Table 2 (continued). Mouse models with increased NST (Harms and Seale 2013). 
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Glucose homeostasis.  Besides the effects on lipid 
metabolism, activation of NST also has major impact on systemic 
glucose homeostasis.  During NST, ATP is generated in BAT through 
glycolysis to compensate for the loss of mitochondrial ATP production.  
Hence, glucose uptake into BAT is strongly enhanced upon cold 
exposure (Greco-Perotto et al. 1987, Vallerand et al. 1990).  
Interestingly, cold-induced glucose uptake into BAT is induced by β-
adrenergic stimulation via an insulin-independent mechanism (Shibata 
et al. 1989).  It has therefore been suggested that activation of NST 
could be used to normalize blood glucose levels in diabetic, insulin-
resistant patients.  However, in contrast to insulin-induced glucose 
uptake, which is mediated through Akt-stimulated translocation of 
GLUT4, much less is known about the mechanism of β-adrenergic 
stimulation-induced glucose uptake.  β-adrenergic stimulation-induced 
glucose uptake is mediated by members of the GLUT transporter 
family (Santalucia et al. 1992).  However, it is not clear whether 
GLUT1 or GLUT4 or both mediate NST-induced glucose uptake.  
Additionally, it has not been fully elucidated whether β-adrenergic 
stimulation-induced glucose uptake involves translocation of glucose 
transporters to the plasma membrane or whether the transporters 
constantly reside in the plasma membrane where they become 
activated upon β-adrenergic stimulation, for example through post-
translational modifications (PTMs) (Palmada et al. 2006).  Hence, in 
order to use β-adrenergic stimulation-induced glucose uptake as a 
treatment option for diabetic patients, it is of importance to elucidate 
the molecular signaling pathways mediating this process. 
 
Origin and function of beige adipose tissue 
Beige adipocytes are the most recently identified adipocyte type.  They 
mainly reside within subcutaneous WAT (sWAT) depots and display an 
intermediate phenotype between white and brown adipocytes (Figure 
6).  The origin of beige adipocytes is still not fully understood.  Beige 
adipocytes are clearly distinct from brown adipocytes, because they do 
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not originate from Myf5 positive precursor cells (Seale et al. 2008).  
Moreover, beige adipocytes express a unique gene signature.  For 
example, the surface markers CD137 and transmembrane protein 26 
(TMEM26) are specifically expressed in beige but not in brown or white 
adipocytes (Wu et al. 2012). However, it is still unclear whether beige 
adipocytes are a distinct cell type or whether they arise via 
transdifferentiation of white adipocytes (Rosen and Spiegelman 
2014). 
Beige adipocytes were discovered due to the observation that 
prolonged cold exposure resulted in the appearance of UCP1-positive 
cells with brown adipocyte-like morphology within WAT depots.  In the 
absence of thermogenic stimuli, beige adipocytes serve as energy 
stores and they display similar rates of uncoupling and energy 
expenditure as white adipocytes.  However, under cold stress, when 
the thermogenic demand of an organism is increased, beige 
adipocytes undergo browning.  Upon browning, β-adrenergic 
stimulation induces expression of brown adipocyte-characteristic 
genes, such as PGC-1α, UCP1, and Dio2 in beige adipocytes (Loncar 
et al. 1988, Loncar 1991, van Marken Lichtenbelt et al. 2009, 
Frontini and Cinti 2010, Rosenwald et al. 2013).  Consequently, 
browning leads to heat production in beige adipocytes and is therefore 
a crucial process to enhance the thermogenic capacity of an organism 
under chronic cold exposure. 
 
mTOR affects adipose tissue biology 
mTORC1 signaling in adipose tissue plays an important role in 
regulating whole body energy expenditure, systemic insulin sensitivity, 
and thermogenesis (Table 1).  Adipose tissue-specific raptor KO 
(AdRaKO) mice with impaired mTORC1 signaling in adipose tissue are 
lean and protected from diet-induced obesity due to increased 
uncoupling in WAT (Polak et al. 2008).  Moreover, AdRaKO mice 
display enhanced systemic insulin sensitivity.  Conversely, adipose 
tissue-specific Grb10 KO mice, which display increased mTORC1 
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signaling in adipose tissue, have decreased energy expenditure due to 
impaired uncoupling and thermogenesis in BAT and WAT, which leads 
to obesity and insulin resistance (Liu et al. 2014) (Table 1).  Thus, 
hyper-activation of mTORC1 signaling in adipose tissue exerts a 
negative effect on whole body metabolism and systemic energy 
homeostasis. 
 mTORC2 signaling in adipose tissue also affects whole body 
metabolism by influencing systemic insulin sensitivity, systemic glucose 
homeostasis and whole-body growth (Table 1).  Adipose-tissue specific 
rictor KO  (AdRiKO) mice, which display impaired mTORC2 signaling in 
adipose tissue, have a strong increase in circulating insulin due to an 
enlarged pancreas (Cybulski et al. 2009).  This substantial increase in 
circulating insulin results in improved systemic glucose tolerance 
despite slight insulin resistance in skeletal muscle and liver.  Moreover, 
upon HFD feeding, AdRiKO mice display an increase in lean mass, 
which results in increased body size (Cybulski et al. 2009).  
Inactivation of mTORC2 signaling specifically in Myf5 positive 
muscle/brown adipocyte progenitors on the other hand increases 
oxidative metabolism in BAT and protects the mice from diet-induced 
obesity due to increased uncoupling without affecting body size (Hung 
et al. 2014) (Table 1). 
 
1.3 mTOR in disease 
 Due to its central role in growth and metabolism, deregulation of mTOR 
signaling is involved in the development of several diseases (Dazert 
and Hall 2011, Laplante and Sabatini 2012).  Figure 9 shows an 
overview of diseases that have been associated with deregulated 
mTOR signaling.  Importantly, many of these diseases are age-related, 
suggesting that mTOR signaling affects aging.  Indeed, 
pharmacological or genetic inhibition of TORC1 signaling results in an 
increased life span in yeast, worms, flies and an increased life- and 
health span in mammals (Vellai et al. 2003, Kapahi et al. 2004, 
Kaeberlein et al. 2005, Powers et al. 2006, Chen et al. 2009, 
Harrison et al. 2009, Anisimov et al. 2010, Bjedov et al. 2010, Miller 
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et al. 2011, Robida-Stubbs et al. 2012, Wilkinson et al. 2012).  Thus, 
mTOR is an attractive target for the treatment of age-related diseases 
and to slow aging. 
      
mTOR in cancer 
Deregulation of mTOR signaling plays a crucial role in the development 
of cancer.  Due to the importance of mTOR in regulating cell growth, 
hyper-activation of mTOR signaling promotes proliferation and cell 
survival and leads therefore to tumor development.  It has been 
estimated that a high percentage of all cancers displays hyper-
activation of mTOR signaling (Shaw and Cantley 2006, Roberts and 
Der 2007).  Interestingly, while mTOR itself is rarely mutated, upstream 
negative regulators of mTOR signaling, such as TSC1/2 and 
phosphatase and tensin homolog (PTEN) are frequently inactivated in 
human tumors (Simpson and Parsons 2001, Curatolo et al. 2008).  
In line with this, genetically modified mice with TSC1/2 or PTEN 
deletion display hyperactive mTOR signaling and consequently 
develop tumors (Yeung et al. 1997, Di Cristofano et al. 1998, Suzuki 
et al. 1998, Podsypanina et al. 1999, Backman et al. 2001, 
Kwiatkowski et al. 2002, Trotman et al. 2003, Wang et al. 2003, 
Figure 9. Diseases linked to deregulated mTOR signaling (Dazert and Hall 
2011). 
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Horie et al. 2004, Wenzel et al. 2004, Meikle et al. 2005, Freeman et 
al. 2006, Meikle et al. 2007, Guertin et al. 2009, Menon et al. 2012, 
Kenerson et al. 2013). These studies demonstrate that hyper-
activation of mTOR signaling is a strong driver of tumorigenesis. 
Many downstream processes regulated by mTOR signaling, 
such as translation, de novo lipogenesis, and cell survival, have been 
shown to be involved in cancer development (Laplante and Sabatini 
2012).  For example, the mTORC1-4E-BP1-eIF4E signaling pathway 
specifically promotes translation of pro-oncogenic mRNAs involved in 
proliferation and metastasis (Thoreen et al. 2012).  Moreover, 
proliferating cancer cells are characterized by an increase in de novo 
lipogenesis in order to generate lipids that are required for the 
synthesis of membranes (Menendez and Lupu 2007).  As mentioned 
earlier, both mTORC1 and mTORC2 stimulate lipogenesis through 
regulation of SREBPs (Duvel et al. 2010, Peterson et al. 2011, 
Hagiwara et al. 2012, Yuan et al. 2012).  Interestingly, depletion of 
SREBPs in TSC2-deficient cells blocks cell proliferation, indicating that 
the lipogenic gene program is required for growth of cells with 
hyperactive mTORC1 signaling (Duvel et al. 2010).  Finally, mTORC2 
is a crucial regulator of cell survival through its main downstream target 
Akt (Zhang et al. 2011). 
Due to the central role of mTOR signaling in cancer 
development, progression and metastasis, the mTOR pathway has 
become an attractive target for cancer therapy.  Thus, many rapamycin 
analogs and mTOR inhibitors are currently tested in clinical trials 
against a large variety of cancers (Wander et al. 2011).  
 
mTOR in obesity and diabetes 
Metabolic disorders develop due to disturbance in energy homeostasis.  
In particular, obesity develops when caloric intake exceeds the amount 
of calories that are burned.  Since mTOR signaling is a nutrient sensor 
and since its activity is modulated by energy, nutrients and growth 
factors, it has been suggested that deregulation of mTOR signaling 
plays a major role in the development of metabolic disorders.  In line 
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with this notion, mice with alterations in mTOR signaling in metabolic 
organs, such as liver, muscle, adipose tissue and hypothalamus, often 
display an aberrant regulation of metabolism and energy homeostasis 
(Table 1, see above for more details).  For example, hyper-activation of 
mTORC1 or inactivation of mTORC2 in the liver leads to glucose 
intolerance and insulin resistance (Sengupta et al. 2010, Kenerson et 
al. 2011, Yecies et al. 2011, Hagiwara et al. 2012).  Hyper-activation 
of mTORC1 or inactivation of mTORC2 in POMC neurons results in 
hyperphagia-induced obesity (Mori et al. 2009, Kocalis et al. 2014).  
Additionally, mice with hyperactive mTORC1 signaling in adipose 
tissue are obese and suffer from metabolic complications (Liu et al. 
2014). Interestingly, mice fed a HFD display increased mTORC1 
signaling in adipose tissue when compared to mice fed a regular diet 
(Polak et al. 2008).  Collectively, these data suggest that, chronic 
activation of mTORC1 signaling in adipose tissue, liver or 
hypothalamus could contribute to the development of diet-induced 
metabolic dysfunction. 
To understand the molecular mechanism(s) involved in the 
development of metabolic disorders, such as cancer, obesity and 
diabetes, it is important to study the role of mTOR signaling in different 
metabolic organs.  Our knowledge on mTOR signaling in regulating cell 
growth and metabolism has dramatically increased in the past couple 
of years.  However, there are still many unanswered questions and 
growing evidence suggests that mTOR signaling has distinct roles in 
different organs (Albert and Hall 2014).  Thus, unraveling novel 
mTOR-regulated processes will hopefully provide new insights into the 
development of metabolic disorders, and help for the design of novel 
treatments against these diseases. 
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2. Aims of the thesis 
 
The overall aim of this thesis was to study mTOR signaling in metabolic 
organs in order to elucidate the impact of organ-specific mTOR signaling 
on organismal energetics.  To address this question, we focused on 
mTORC1 in the hypothalamus and on mTORC2 in adipose tissue and 
studied their role in regulating systemic energy homeostasis. 
In the first part of this thesis, we investigated the role of mTORC1 
signaling in hypothalamic Agrp neurons with particular focus on the impact 
of impaired mTORC1 signaling in these neurons on feeding behavior and 
whole-body energy metabolism.  In the second part of this thesis we 
studied whether and how mTORC2 signaling in adipose tissue regulates 
thermogenesis and whole body energy expenditure.  With these studies 
we hope to provide a better understanding of the molecular mechanisms 
involved in the regulation of systemic energy homeostasis.  This 
knowledge could help develop novel treatment strategies against obesity 
and obesity-associated diseases.  Obesity is a strong risk factor for the 
development of several other diseases, such as diabetes, cardiovascular 
disease and cancer.  Alarmingly, the prevalence of obesity has drastically 
increased during the last decades in both developing and developed 
countries (Ng et al. 2014).  Since obesity develops due to a sedentary 
lifestyle and an excess of calorie intake, an efficient and cost-effective way 
to ameliorate metabolic dysfunction in obese patients would be to increase 
physical activity and reduce calorie intake in the patients.  However, 
maintaining diet and exercise regimens is challenging and has therefore 
shown only moderate success as an anti-obesity treatment in obese 
patients.  In light of this, there is a need for novel therapies aimed at 
reducing obesity, and thereby reducing the prevalence of metabolic 
diseases in the population.  
Recently, it has become evident that dysfunction of hypothalamic 
neurons involved in feeding behavior often contributes to the development 
of obesity (Velloso et al. 2009).  For example, many obese patients 
display leptin and insulin resistance in Agrp and POMC neurons, which 
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deregulates normal feeding behavior and thereby leads to metabolic 
dysfunction (Williams 2012).  Hence, unraveling the molecular signaling 
pathways that regulate Agrp and POMC neuronal function could provide a 
better understanding of the molecular mechanisms which regulate feeding 
behavior and energy homeostasis and could in extension lead to the 
development of novel anti-obesity treatments.  Due to the important role of 
mTORC1 as a nutrient and energy sensor, mTORC1 could potentially be 
involved in the regulation of Agrp and POMC neuronal function.  Indeed, 
POMC-specific hyper-activation of mTORC1 signaling leads to 
hyperphagia-induced obesity due to impaired POMC expression (Mori et 
al. 2009).  This indicates that mTORC1 signaling is crucial for POMC 
function.  However, the role of mTORC1 signaling in Agrp neurons has so 
far not been thoroughly examined. 
Thus, in the first part of this thesis we focused on elucidating the 
role of mTORC1 signaling in Agrp neurons of the hypothalamus.  To this 
end we generated Agrp neuron-specific raptor (Agrp-raptor) KO mice to 
inactivate mTORC1 signaling specifically in Agrp neurons and analyzed 
the systemic metabolic phenotype of these mice.  With this project we 
wanted to answer the following questions: 
 
1.  Does inactivation of mTORC1 signaling in Agrp neurons alter 
feeding behavior and/or systemic energy homeostasis? 
2.   How do Agrp-raptor KO mice react to a dietary challenge, such 
as HFD feeding? 
3.  Is mTORC1 signaling involved in the regulation of orexigenic 
neuropeptide expression? 
 
In the second part of this thesis we investigated whether mTORC2 
signaling in adipose tissue regulates non-shivering thermogenesis (NST) 
and thereby affects systemic energy homeostasis.  Activation of NST and 
subsequent energy dissipation has been proposed as an alternative 
strategy to treat obesity and decrease the risk for obesity-associated 
diseases (Clapham and Arch 2011).  Additionally, cold-induced glucose 
uptake into BAT through an insulin-independent mechanism could provide 
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a promising therapy to decrease blood glucose in insulin-resistant, diabetic 
patients.  Thus, identifying novel molecular pathways involved in the 
regulation of NST could help develop novel therapies for obesity and 
diabetes.  Since mTORC2 signaling is an important regulator of insulin-
stimulated glucose uptake and glycolysis, we hypothesized that mTORC2 
signaling in BAT could be involved in the regulation of cold-induced 
glucose uptake and temperature homeostasis.  To test this hypothesis, we 
used AdRiKO mice, where mTORC2 signaling is specifically inactivated in 
mature adipocytes, and investigated how these mice responded to 
thermogenic stimuli, such as cold exposure or β-adrenergic stimulation.  
With this second project we wanted to answer the following questions: 
 
1.  How is mTORC2 signaling in BAT and WAT regulated upon 
cold exposure or β-adrenergic stimulation? 
2.  Does inactivation of mTORC2 signaling in adipose tissue affect 
body temperature and/or cold tolerance? 
3.  Is mTORC2 signaling in BAT involved in cold-induced glucose 
uptake? 
 
With these two projects we hope to provide a better understanding of how 
mTOR signaling in a particular tissue can affect whole-body metabolism and 
thereby influence systemic energy homeostasis.  This knowledge could 
potentially lead to new drug targets for anti-obesity therapies.	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Abstract 
Orexigenic agouti-related protein/neuropeptide Y (Agrp/NPY) neurons and 
anorexigenic pro-opiomelanocortin (POMC) neurons of the hypothalamus 
regulate feeding behavior and energy homeostasis.  An understanding of the 
molecular signaling pathways that regulate Agrp/NPY and POMC function 
could lead to novel treatments for metabolic disorders.  Target of Rapamycin 
Complex 1 (TORC1) is a nutrient activated protein kinase and central 
controller of growth and metabolism.  We therefore investigated the role of 
mammalian TORC1 (mTORC1) in Agrp neurons.  We generated and 
characterized Agrp neuron-specific raptor knockout (Agrp-raptor KO) mice.  
Agrp-raptor KO mice displayed reduced, non-circadian expression of Agrp 
and NPY but normal feeding behavior and energy homeostasis on both 
normal and high fat diet.  Thus, mTORC1 in Agrp neurons controls circadian 
expression of orexigenic neuropeptides but is dispensable for the regulation of 
feeding behavior and energy metabolism. 
 
Keywords: mTORC1; raptor; hypothalamus; Agrp; NPY; metabolism 
 
Introduction 
The arcuate nucleus (ARC) of the hypothalamus mediates whole body energy 
homeostasis including feeding behavior.  It contains orexigenic agouti-related 
protein/neuropeptide Y (Agrp/NPY) neurons that secrete the neuropeptides 
Agrp and NPY, and anorexigenic pro-opiomelanocortin (POMC) neurons that 
secrete the neuropeptide POMC.  Agrp/NPY neurons induce feeding and 
decrease energy expenditure while POMC neurons inhibit feeding and 
increase energy expenditure (Cone et al. 2001, Neary et al. 2004, Arora and 
Anubhuti 2006).  The ARC receives input from peripheral organs via 
hormones, such as insulin from the pancreas, leptin from adipose tissue and 
ghrelin from the intestine (Woods 2009). Thus, dysfunction of Agrp/NPY and 
POMC neurons can contribute to the development of obesity (Velloso et al. 
2009).  For example, Agrp/NPY and POMC neurons of obese patients often 
develop resistance to leptin and insulin, leading to altered feeding behavior 
and disturbed energy metabolism (Williams 2012).  It is therefore important to 
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understand the signaling pathways that regulate Agrp/NPY and POMC 
function. 
The mammalian Target of Rapamycin (mTOR) signaling pathway 
integrates energy and nutrient levels to regulate cellular and organismal 
growth and metabolism (Laplante and Sabatini 2012, Dibble and Manning 
2013, Albert and Hall 2014, Shimobayashi and Hall 2014).  mTOR forms 
two structurally and functionally distinct complexes, mTOR complex 1 
(mTORC1) and mTORC2 (Wullschleger et al. 2006).  mTORC1 is activated 
by growth factors, amino acids and cellular energy.  Activation of mTORC1 by 
growth factors is mediated via the PI3K-PDK1-Akt signaling pathway.  
mTORC1 signaling stimulates protein synthesis, nucleotide biosynthesis, and 
lipogenesis, while it inhibits autophagy (Dibble and Manning 2013, 
Shimobayashi and Hall 2014).  Due to its central role in cell growth and 
metabolism, deregulation of mTORC1 signaling is often associated with the 
development of metabolic disorders, such as diabetes and obesity (Dazert 
and Hall 2011).  Several studies have implicated hypothalamic mTORC1 
signaling in the regulation of energy homeostasis and food intake.  For 
example, feeding status regulates mTORC1 activity in both Agrp/NPY and 
POMC neurons (Cota et al. 2006), and hyperactivation of mTORC1 in POMC 
neuron leads to hyperphagia-induced obesity (Mori et al. 2009).   
To further examine the role of mTORC1 signaling in the ARC, we 
generated Agrp neuron-specific raptor knockout (Agrp-raptor KO) mice and 
assessed whole body energy metabolism, feeding behavior and adaptation to 
metabolic stress.  Ablation of mTORC1 signaling in Agrp neurons resulted in 
reduced, non-circadian expression of orexigenic neuropeptides.  However, 
this did not affect ad libitum food intake or ghrelin- or fasting-induced feeding.  
Furthermore, neither male nor female Agrp-raptor KO mice displayed changes 
in whole-body metabolism compared to control mice.  On both normal and 
high fat diet (HFD), Agrp-raptor KO mice displayed similar body weight, 
glucose homeostasis and whole-body metabolic rates compared to control 
mice.  Hence, mTORC1 signaling in Agrp neurons is dispensable for 
regulation of whole-body metabolism and feeding behavior.  
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Material and Methods 
Animals. Agrp-raptor KO mice were generated by crossing Agrp-IRES-Cre 
mice (Tong et al. 2008) with raptorLoxP/LoxP mice (Polak et al. 2008). For 
immunohistochemistry Agrp-IRES-Cre or Agrp-raptor KO mice were crossed 
with Rosa26-STOP LoxP/LoxP-EGFP mice (Mao et al. 2001) to obtain mice with 
EGFP expression in Agrp neurons.  Mice were housed at 22°C in a 
conventional facility with a 12h light/12h dark cycle.  The standard diet 
contained 15.8kcal% of fat (Promivi Kliba).  The high fat diet contained 
60kcal% of fat (Harlan).  All experiments were performed in accordance with 
the federal guidelines for animal experimentation and were approved by the 
Kantonales Veterinäramt of Kanton Basel-Stadt. 
 
Locomotor Activity, Metabolic Rate, and Food Intake.  Locomotor activity, 
metabolic rate, and food intake was measured for 48h using a comprehensive 
laboratory animal monitoring system (CLAMS, Linton Instrumentation and 
Columbus Instruments) after 24h of acclimatization. 
 
Glucose Tolerance Test.  Mice were starved for 6h and subsequently 
injected I.P. with glucose (2g/kg).  Blood glucose was measured in tail vain 
blood using a glucose meter (Accu-Chek, Roche).  
 
Microdissection of ARC.  ARC was isolated from brains by micropunch 
(Palkovits 1973).  Brains were sliced in 0.5mm thick coronal sections with a 
rodent brain slicer matrix (Zivic Instruments).  Sections containing the ARC 
were identified and ARC was excised with a hollow needle (1.25mm 
diameter). 
 
RNA Isolation and RT-PCR.  Total RNA from hypothalamus or ARC was 
isolated with SV total RNA isolation kit (Promega) followed by cDNA synthesis 
using iScript cDNA synthesis kit (Bio-Rad).  Semi-quantitative real-time PCR 
analysis was performed using fast SYBR green (Applied Biosystems) on a 
StepOnePlus Real-Time PCR System (Applied Biosystems).  Relative 
expression levels were determined by normalizing to TBP expression using 
the ΔΔCt method. 
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Primers used: 
TBP fw: TGCTGTTGGTGATTGTTGGT 
TBP rv: CTGGCTTGTGTGGGAAAGAT 
Agrp fw: AACCTCTGTAGTCGCACCTAGC 
Agrp rv: AAACCGTCCCATCCTTTATTCT 
NPY fw: AGGCTTGAAGACCCTTCCAT 
NPY rv: GATGAGGGTGGAAACTTGGA 
POMC fw: GAGCTGATGACCTCTAGCCTCT 
POMC rv: ATCAGAGCCGACTGTGAAATCT. 
 
Protein Isolation and Western Blot.  Hypothalamus or ARC tissue was 
homogenized in lysis buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM 
EDTA, 1% Triton X-100, protease inhibitors (Roche) and phosphatase 
inhibitors (Sigma-Aldrich)).  Proteins were separated on SDS-PAGE and 
transferred onto nitrocellulose membranes (Whatman).  Antibodies used: Akt 
(Santa Cruz), Akt-pS473, Akt-pT308, S6, S6-pS235/236, 4E-BP1, 4EBP1-
pS37/48 (all Cell Signaling), actin (Millipore) 
 
Recombination.  Genomic DNA was isolated by incubating the tissues in 
PBND buffer containing 0.1mg Proteinase K at 57°C over night, followed by 
proteinase K inactivation at 95°C for 10 minutes.  PCR was performed for Cre 
or for the genomic region flanking the floxed sites in the raptor gene to 
determine raptor deletion.  Primers used: Cre fw: 
TGTGGCTGATGATCCGAATA; Cre rv: GCTTGCATGATCTCCGGTAT; 
raptor deletion fw: ATGGTAGCAGGCACACTCTTCATG; raptor deletion rv:  
CTCAGAGAACTGCAGTGCTGAAGG. 
 
Immunostaining.  Mice were transcardially perfused with 4% 
paraformaldehyde, followed by over night fixation of the brain in 4% 
paraformaldehyde.  Brains were dehydrated, embedded in paraffin and cut in 
5um thick coronal sections.  Antibodies used: GFP (Abcam) and pS6 
S235/236 (Cell Signaling). DAPI was used to stain the nuclei. 
 
Blood Analysis.  Blood glucose was measured in tail vain blood using a 
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glucose meter (Accu-Chek, Roche). 
 
Fasting refeeding.  Mice were starved over night prior to the experiment.  At 
ZT2 mice were refed and food was weighted at the indicated times after 
refeeding. 
 
Ghrelin stimulation.  Mice were fed ad libitum and injected I.P. with 1mg/kg 
of ghrelin or vehicle.  Food intake was measured 30 minutes after ghrelin 
administration. 
 
Results 
Deletion of raptor in Agrp neurons leads to inactivation of mTORC1 
signaling.  To investigate the role of mTORC1 signaling in Agrp neurons, we 
generated Agrp-raptor KO mice by crossing Agrp-IRES-Cre mice (Tong et al. 
2008) with raptorLoxP/LoxP mice (Polak et al. 2008).  To assess the tissue 
specificity of the knockout, we performed PCR to monitor raptor ablation.  
Excision of the floxed raptor allele was detected in the ARC of Agrp-raptor KO 
mice while the hypothalamic region surrounding the ARC and all other organs 
tested revealed an intact raptor gene (Figure 1A).  Thus, raptor ablation was 
specific to the ARC.  Next, we investigated PI3K-mTORC1 signaling in the 
ARC of control and Agrp-raptor KO mice in a fasting-refeeding paradigm.  In 
the ARC of control mice, feeding induced phosphorylation of Akt at S473 and 
of the mTORC1 target S6 at S235/236 (Figure 1B).  These findings 
demonstrate that the PI3K-mTORC1 signaling pathway is activated in the 
ARC upon feeding, as shown previously (Cota et al. 2006).  In contrast, 
phosphorylation of S6 at S235/236 was absent in the ARC of Agrp-raptor KO 
mice, indicating that mTORC1 signaling was indeed inactive upon knockout of 
raptor (Figure 1B).  In line with previous studies using raptor-deficient mouse 
models (Bentzinger et al. 2008, Polak et al. 2008), Agrp-raptor KO mice 
displayed hyper-phosphorylation of Akt-S473 and -T308 in the ARC (Figure 
1B), due to absence of the S6K-mediated negative feedback loop 
(Harrington et al. 2004, Shah et al. 2004, Um et al. 2004, Harrington et al. 
2005).  To assess mTORC1 signaling specifically in Agrp neurons, we 
immunostained phospho-S6 in coronal brain sections of Agrp-raptor KO and 
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control mice expressing EGFP specifically in Agrp neurons.  In line with our 
previous findings (Figure 1B), S6 phosphorylation was induced in Agrp 
neurons upon refeeding in control mice (Figure 1C), but was absent in Agrp 
neurons of Agrp-raptor KO mice.  Thus, as expected, mTORC1 signaling was 
defective in Agrp neurons upon raptor deletion. 
 
Inactivation of mTORC1 signaling in Agrp neurons does not affect 
whole-body metabolism.  To investigate the role of mTORC1 signaling in 
Agrp neurons on whole-body metabolism, we measured body weight, body 
composition, glucose tolerance, metabolic rate and locomotor activity in young 
(3 months old) and old (1 year old) Agrp-raptor KO and control mice.  
Surprisingly, Agrp-raptor KO mice did not display any differences in body 
weight (Figure 2A), body composition (Figure 2B) or glucose tolerance 
(Figure 2C) compared to control mice at either age. In the aged group, Agrp-
raptor KO mice showed a trend toward higher body weight compared to 
control littermates (Figure 2A). However, this difference did not reach 
statistical significance.  Moreover, there was no difference in oxygen 
consumption (Figure 2D), carbon dioxide production (Figure 2E), respiratory 
exchange ratio (Figure 2F) and locomotor activity (Figure 2G) in Agrp-raptor 
KO mice compared to control mice. Taken together, these findings 
demonstrate that inactivation of mTORC1 signaling in Agrp neurons does not 
affect whole-body metabolism in either young or aged mice. 
 
Agrp-raptor KO mice display impaired circadian rhythm of Agrp and 
NPY expression but not altered feeding behavior.  Since Agrp neurons 
regulate feeding behavior in a circadian manner, we investigated food intake, 
mTORC1 signaling, and Agrp and NPY mRNA expression levels over a 24h 
cycle in Agrp-raptor KO and control mice fed ad libitum.  Mice were sacrificed 
at Zeitgeber 0 (ZT0), ZT12, ZT18 and ZT24.  At ZT0, the lights turn on, ZT12 
marks when the light turns off.  Similar to other organs (Cao et al. 2011, 
Cornu et al. 2014, Khapre et al. 2014), phosphorylation of the mTORC1 
downstream targets S6 (S235/236) and 4E-BP1 (T37/48) was regulated in a 
circadian manner in the ARC of control mice.  mTORC1 signaling activity in 
the ARC peaked at ZT18, during the dark phase when mice are active and eat 
Dissertation - mTOR signaling in organismal energetics 
	   62 
(Figure 3A).  In Agrp-raptor KO mice, phosphorylation of S6 and 4E-BP1 was 
undetectable in the ARC at all time points, confirming that mTORC1 signaling 
was ablated (Figure 3A).  Importantly, mRNA expression of both Agrp and 
NPY also oscillated in a circadian manner similar to mTORC1 signaling 
activity (Figure 3B).  Similar to S6 (S235/236) and 4E-BP1 (T37/48) 
phosphorylation, Agrp and NPY expression was highest at ZT18 (Figure 3B).  
Interestingly, expression of both Agrp and NPY was reduced and non-
oscillating in Agrp-raptor KO mice, leading to a significant reduction in Agrp 
and NPY levels at ZT18 (Figure 3B). Hence, the circadian pattern of 
mTORC1 signaling in the ARC might regulate the circadian oscillation of Agrp 
and NPY expression.   In contrast to this, POMC expression was not circadian 
and did not differ between the genotypes (Figure 3B).  Thus, inactivation of 
mTORC1 in Agrp neurons does not lead to compensatory alterations in 
POMC levels.  Surprisingly, despite a significant decrease in Agrp and NPY 
mRNA levels, Agrp-raptor KO mice did not display a decrease in ad libitum 
food intake compared to controls (Figure 3C). 
 Since Agrp and NPY expression was reduced in Agrp-raptor KO mice, 
we hypothesized that induction of Agrp and NPY expression might also be 
impaired in starved KO mice.  To test this, we measured Agrp and NPY 
mRNA in Agrp-raptor KO and control mice that were starved overnight or fed 
ad libitum.  Unlike the decreased circadian Agrp and NPY expression, Agrp-
raptor KO mice were able to induce both Agrp and Npy mRNA expression 
upon fasting (Figure 3D).  Hence, induction of Agrp and NPY mRNA upon 
fasting is likely mediated by an mTORC1-independent mechanism.  In line 
with the unchanged induction of Agrp and NPY expression upon starvation, 
Agrp-raptor KO mice displayed similar feeding in response to a fasting-
refeeding challenge as compared to control mice.  We fasted Agrp-raptor KO 
and control mice overnight and measured food intake after refeeding in the 
morning. Agrp-raptor KO mice consumed a similar amount of food compared 
to control mice at all time points after refeeding (Figure 3E).  Next, we 
investigated whether mTORC1 signaling is required for induction of feeding 
upon ghrelin stimulation.  Ghrelin is an orexigenic neuropeptide that is 
secreted upon starvation from ghrelin-producing cells in the gastrointestinal 
tract and is able to activate Agrp neurons (Nakazato et al. 2001, Wren et al. 
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2001).  We injected fed Agrp-raptor KO and control mice with ghrelin and 
measured food intake.  Similar to our results above, Agrp-raptor KO mice 
again failed to display a defect in food intake (Figure 3F).  The above taken 
together indicates that feeding behavior is not impaired in Agrp-raptor KO 
mice. 
 
Agrp-raptor KO mice respond to metabolic stress.  Chronic, excessive 
consumption of nutrients, in particular fat, is a metabolic stress that induces 
compensatory metabolic alterations.  Since Agrp-raptor KO mice failed to 
display metabolic alterations when fed a standard diet, we investigated the 
response of Agrp-raptor KO mice to metabolic stress.  To induce metabolic 
stress, we fed Agrp-raptor KO and control mice a high fat diet (HFD) (60kcal% 
from fat) for 10 weeks.  Similar to the results obtained on a normal diet, Agrp 
raptor-KO mice displayed similar weight gain compared to controls (Figure 
4A).  Moreover, body composition and food intake did not significantly differ 
between the genotypes (Figure 4B and 4C).  To assess glucose tolerance in 
HFD-fed Agrp-raptor KO mice we performed an intraperitoneal glucose 
tolerance test (GTT) and measured blood glucose in both fasted and fed 
animals.  While HFD feeding led to impaired glucose tolerance in control and 
Agrp-raptor KO mice, no difference in glucose clearance rates could be 
detected between genotypes (Figure 4D).  Furthermore, control and Agrp-
raptor KO mice displayed similar blood glucose levels upon HFD feeding 
(Figure 4E).  Finally, we measured oxygen consumption (Figure 4F), carbon 
dioxide production (Figure 4G), respiratory exchange ratio (Figure 4H), and 
locomotor activity (Figure 4I) in Agrp-raptor KO and control mice fed a HFD.  
In line with our results obtained with mice on a normal diet, HFD-fed Agrp-
raptor KO mice failed to display any alteration in these parameters as 
compared to control mice.  Taken together, these findings demonstrate that 
ablation of mTORC1 signaling in Agrp neurons does not alter the response to 
metabolic stress such as that caused by a HFD. 
 
Discussion 
mTOR is a nutrient sensor.  Consequently, mTORC1 signaling in the 
hypothalamus has been suggested to be involved in the regulation of whole 
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body energy homeostasis and feeding behavior.  Indeed, hyper-activation of 
mTORC1 signaling specifically in POMC neurons through knockout of TSC1 
results in hyperphagia-induced obesity (Mori et al. 2009).  These findings 
demonstrate a role for mTORC1 signaling in POMC neurons in the regulation 
of feeding behavior.  However, the role of mTORC1 signaling in Agrp neurons 
has so far not been thoroughly examined.  To elucidate the role of mTORC1 
signaling in these neurons, we generated Agrp-raptor KO mice.  Surprisingly, 
Agrp-raptor KO mice displayed no impairment in whole-body energy 
metabolism, glucose homeostasis and feeding behavior, both on normal and 
high fat diet.  Hence, mTORC1 signaling in Agrp neurons is dispensable for 
the regulation of energy balance and feeding behavior.  This is in agreement 
with a recent publication demonstrating that hyper-activation of mTORC1 in 
Agrp neurons, through deletion of TSC1, did not affect feeding behavior or 
energy homeostasis (Yang et al. 2012).  Thus, disruption of mTORC1 
signaling in POMC neurons seemingly affects whole-body energy 
homeostasis, whereas perturbation of mTORC1 signaling in Agrp neurons 
does not.  Interestingly, similar to mTORC1, Agrp-specific inactivation of 
mTORC2 signaling through deletion of rictor did not result in any alterations in 
feeding behavior and energy homeostasis, while POMC-specific deletion of 
rictor caused hyperphagia-induced obesity (Kocalis et al. 2014).  
These findings are in line with the observation that perturbation of 
POMC neuronal function has a more profound effect on feeding behavior and 
energy metabolism as compared to perturbation of Agrp/NPY neuronal 
function.  For example, inhibition of Agrp or NPY expression does not affect 
feeding behavior (Erickson et al. 1996, Marsh et al. 1998, Palmiter et al. 
1998, Qian et al. 2002).  In contrast, impaired POMC expression or POMC 
neuronal function results in hyperphagia, obesity and disturbance in energy 
homeostasis (Krude et al. 1999, Yaswen et al. 1999).  While depletion of 
Agrp neurons in neonates only mildly affects feeding behavior, ablation of 
Agrp neurons in adult mice results in a strong decrease in food intake, leading 
to starvation (Luquet et al. 2005).  These findings imply that the requirement 
for Agrp neurons for the regulation of feeding can be circumvented when their 
function is impaired early in life.  A limitation of the Agrp-raptor KO mice used 
in this study is therefore that mTORC1 signaling is inactivated in Agrp 
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neurons already in the neonate state.  It could thus be that compensatory 
mechanisms have developed to circumvent the requirement for mTORC1 
signaling for Agrp neuronal function in Agrp-raptor KO mice.  Future studies 
should address whether disruption of mTORC1 signaling in Agrp neurons in 
adult mice impacts energy homeostasis and feeding behavior. 
We found that Agrp-raptor KO mice display impaired circadian 
expression of Agrp and NPY but normal feeding behavior.  Interestingly, 
mTORC1 activity in the ARC of control mice was highest during the dark 
phase, similar to the expression pattern of Agrp and NPY mRNA.  Since Agrp-
raptor KO mice were unable to induce mTORC1 signaling in Agrp neurons 
during the dark phase, it is likely that circadian mTORC1 signaling regulates 
circadian Agrp and NPY mRNA expression.  In contrast to the defective Agrp 
and NPY expression observed in ad libitum fed mice, Agrp-raptor KO mice 
strongly induced Agrp and NPY mRNA expression in response to overnight 
starvation as observed in control mice.  Importantly, mTORC1 activity was low 
in the ARC of control mice after overnight starvation.  These finding suggest 
that the induction of Agrp and NPY mRNA expression after overnight 
starvation is mTORC1-independent and thus mechanistically different 
compared to the circadian regulation of Agrp and NPY mRNA expression.  
Future studies should be aimed at identifying the molecular basis for this 
difference in the regulation of NPY and Agrp expression. 
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Figure 1.  Deletion of raptor in Agrp neurons leads to inactivation of mTORC1 
signaling.  (A) PCR for Cre and raptor deletion in the indicated organs from 
Agrp-raptor KO mice.  (B) Immunoblot of protein lysates from the ARC of 
Agrp-raptor KO and control mice with the indicated antibodies.  (C) 
Immunostaining of coronal brain sections from Agrp-raptor KO reporter mice 
and control reporter mice for EGFP to visualize Agrp neurons and S6-
pS235/236 to visualize mTORC1 activity. 
3. Results, Manuscript 2 
67 
 
 
Figure 2.  Inactivation of mTORC1 signaling in Agrp neurons does not affect 
whole-body metabolism.  (A) Body weight of young and old Agrp-raptor KO 
and control mice.  (B) Body composition of young and old Agrp-raptor KO and 
control mice.  (C) GTT of young and old Agrp-raptor KO and control mice.  (D) 
Oxygen consumption (VO2) of young and old Agrp-raptor KO and control 
mice.  (E) Carbon dioxide production (VCO2) of young and old Agrp-raptor KO 
and control mice.  (F) Respiratory exchange ratio (RER) of young and old 
Agrp-raptor KO and control mice.  (G) Locomotor activity of young and old 
Agrp-raptor KO and control mice.  Data represent mean ± SEM.  Statistically 
significant differences between Agrp-raptor KO and control mice are indicated 
with asterisks (*=p<0.05; **=p<0.01, ***=p<0.001). 
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Figure 3.  Agrp-raptor KO mice display impaired circadian rhythm of Agrp and 
NPY expression but not altered feeding behavior.  (A) Immunoblot analysis 
with the indicated antibodies of protein lysates from the ARC of Agrp-raptor 
KO and control mice sacrificed at the indicated time points.  (B) qRT-PCR 
analysis of Agrp, NPY and POMC mRNA in the hypothalamus of Agrp-raptor 
KO and control mice sacrificed at the indicated time points.  (C) Ad libitum 
food intake of Agrp-raptor KO and control mice.  (D) qRT-PCR analysis of 
Agrp and NPY mRNA in the hypothalamus of Agrp-raptor KO and control 
mice fed ad libitum or starved over night.  (E) Refeeding response of Agrp-
raptor KO and control mice after over night starvation.  (H) Feeding response 
of Agrp-raptor KO and control mice after ghrelin injection. Data represent 
mean ± SEM.  Statistically significant differences between Agrp-raptor KO and 
control mice are indicated with asterisks (*=p<0.05; **=p<0.01, ***=p<0.001).  
Statistically significant differences between feeding conditions or ghrelin 
stimulation are indicated with a number sign (#=p<0.05; ##=p<0.01; 
###=p<0.001). 
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Figure 4.  Agrp-raptor KO mice respond to metabolic stress.  (A) Body weight 
of HFD fed Agrp-raptor KO and control mice.  (B) Body composition of HFD 
fed Agrp-raptor KO and control mice.  (C) Food intake of HFD fed Agrp-raptor 
KO and control mice. (D) GTT of HFD fed Agrp-raptor KO and control mice. 
(E) Fasted and fed ad libitum blood glucose levels of HFD fed Agrp-raptor KO 
and control mice.  (F) Oxygen consumption (VO2) of HFD fed Agrp-raptor KO 
and control mice.  (G) Carbon dioxide production (VCO2) of HFD fed Agrp-
raptor KO and control mice.  (H) Respiratory exchange ratio (RER) of HFD fed 
Agrp-raptor KO and control mice.  (I) Locomotor activity of HFD fed Agrp-
raptor KO and control mice.  Data represent mean ± SEM. 
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Abstract 
Activation of non-shivering thermogenesis (NST) in brown adipose tissue 
(BAT) has been proposed as an anti-obesity treatment.  Moreover, cold-
induced glucose uptake could normalize blood glucose levels in insulin 
resistant patients.  It is therefore important to identify novel regulators of NST 
and cold-induced glucose uptake.  Mammalian Target of Rapamycin Complex 
2 (mTORC2) mediates insulin-stimulated glucose uptake in metabolic tissues 
but its role in NST is unknown.  We show that mTORC2 is activated in brown 
adipocytes upon β-adrenergic stimulation.  Furthermore, mice lacking 
mTORC2 specifically in adipose tissue (AdRiKO mice) are hypothermic, 
display increased sensitivity to cold, and show impaired cold-induced glucose 
uptake and glycolysis.  Restoration of glucose uptake in BAT by 
overexpression of hexokinase II or activated Akt2 was sufficient to increase 
body temperature and improve cold tolerance in AdRiKO mice.  Thus, 
mTORC2 in BAT mediates temperature homeostasis via regulation of cold-
induced glucose uptake. 
 
Keywords: brown adipose tissue, thermogenesis, mTORC2, glucose uptake 
 
Introduction 
Non-shivering thermogenesis (NST) in brown adipose tissue (BAT) allows 
mammals to maintain stable body temperature in a cold environment.  Upon 
cold exposure, norepinephrine (NE) is released from sympathetic nerves and 
binds to β3-adrenergic receptors on brown adipocytes to induce NST.  β3-
adrenergic receptor stimulation induces cAMP production and subsequent 
induction of lipolysis, β-oxidation and mitochondrial uncoupling (Cannon and 
Nedergaard 2004).  Mitochondrial uncoupling occurs through activation of 
uncoupling protein 1 (UCP1).  UCP1 is a mitochondrial transmembrane 
protein specifically expressed in brown adipocytes and brown-like, beige 
adipocytes.  Once activated, UCP1 dissipates the proton gradient across the 
inner mitochondrial membrane generated by the electron transport chain.  
This uncouples proton flux into the mitochondria from ATP production, 
resulting in heat generation (Klaus et al. 1991, Busiello et al. 2015).  To 
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compensate for the loss of mitochondrial ATP production due to uncoupling, 
β-adrenergic stimulation enhances glucose uptake and glycolysis in BAT 
(Greco-Perotto et al. 1987, Vallerand et al. 1990, Hao et al. 2015).  Due to 
the ability of BAT to burn energy efficiently and to reduce blood glucose 
levels, activation of NST has been proposed as an alternative strategy for 
weight loss in obese patients (Cypess et al. 2009, van Marken Lichtenbelt 
et al. 2009, Virtanen et al. 2009, Clapham and Arch 2011) and for 
normalization of blood glucose levels in insulin resistant diabetic patients.  
Thus, identifying novel regulators of NST could provide new drug targets for 
anti-obesity and diabetes treatments. 
 The mammalian target of rapamycin (mTOR) signaling network is a 
central regulator of cell growth and metabolism (Laplante and Sabatini 2012, 
Dibble and Manning 2013, Albert and Hall 2014, Shimobayashi and Hall 
2014).  mTOR is a highly conserved protein kinase found in two structurally 
and functionally distinct complexes named mTOR complex 1 (mTORC1) and 
mTORC2.  mTORC1 is sensitive to the macrolide rapamycin, and contains 
mTOR, mammalian lethal with sec-13 protein (mLST8), and regulatory 
associated protein of mTOR (raptor).  mTORC2 is rapamycin-insensitive, 
contains mTOR, mLST8, mammalian stress-activated map kinase-interacting 
protein 1 (mSIN1), and rapamycin insensitive companion of mTOR (rictor).  
mTORC2 is activated by growth factors, such as insulin and insulin-like 
growth factor 1 (IGF-1), via phosphatidylinositol 3-kinase (PI3K)-dependent 
ribosome association (Zinzalla et al. 2011).  mTORC2 downstream targets 
are members of the AGC kinase family, such as Akt, serum/glucocorticoid 
regulated kinase (SGK) and protein kinase C (PKC) (Sarbassov et al. 2005, 
Jacinto et al. 2006, Garcia-Martinez and Alessi 2008, Ikenoue et al. 2008, 
Cybulski and Hall 2009), through which mTORC2 promotes lipogenesis, 
glucose uptake, glycolysis, and cell survival (Manning and Cantley 2007, 
Kumar et al. 2008, Hagiwara et al. 2012, Yuan et al. 2012).  Due to its role 
in mediating lipid and glucose homeostasis, dysfunction of mTORC2 signaling 
has been implicated in the development of insulin resistance and diabetes.  
However, a role for mTORC2 in thermogenesis, and in particular NST, has so 
far not been investigated. 
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 Here we show that β-adrenergic stimulation and cold exposure activate 
mTORC2 signaling in brown adipocytes in vitro and in vivo.  We find that 
mTORC2 in BAT stimulates cold-induced glucose uptake and glycolysis.  
Consequently, mice with adipose tissue-specific inactivation of mTORC2 
(AdRiKO mice) are hypothermic and unable to maintain stable body 
temperature upon cold exposure.  Restoration of either Akt signaling or 
glucose metabolism in BAT of AdRiKO mice restored body temperature and 
improved cold tolerance.  Thus, mTORC2 in BAT is essential for maintenance 
of energy homeostasis and body temperature upon cold exposure. 
 
Material and Methods 
Cell Culture.  SV40T-immortalized C57/B6 mouse brown pre-adipocytes 
were kindly provided by Professor Johannes Klein (Lübeck, Germany) (Klein 
et al. 2002).  Preadipocytes were grown to confluency in Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 20% fetal calf 
serum (FCS), 4.5g/L glucose, 2mM glutamine, 20nmol/L insulin, and 1nmol/L 
triiodothyronine.  24h after reaching confluency, adipocyte differentiation was 
induced by addition of 250umol/L indomethacin, 500umol/L 
isobutylmethylxanthine and 2ug/mL dexamethasone to the medium for 24h.  
Cell culture was continued for five more days before experiments were 
performed. 
 
Animals.  Adipose tissue-specific rictor knockout mice (AdRiKO) were 
already described and characterized previously (Cybulski et al. 2009).  Mice 
were housed at 22°C in a conventional facility with a 12h light/ 12h dark cycle.  
For all experiments male aP2-Cre; rictorLoxP/LoxP (AdRiKO) and rictorLoxP/LoxP (control) 
mice between 10-14 weeks of age were used.  All experiments were 
performed in accordance with the federal guidelines for animal 
experimentation and were approved by the Kantonales Veterinäramt of 
Kanton Basel-Stadt. 
 
In vivo Norepinephrine Stimulation.  Mice were starved for 12h over night 
prior to norephinephrine administration.  Mice were injected intraperitoneally 
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with 1mg/kg norepinephrine and sacrificed 30 minutes later. 
 
Cold Exposure. Mice were housed in single cages with free access to water 
at 4°C for a period of 2h, 4h, or 8h. For the 4h and 8h cold exposure, food 
was removed specifically during cold exposure.  For the 2h cold exposure 
food was removed 12h prior to cold exposure and during cold exposure to 
allow assessment of mTORC2 signaling. 
 
Thermoneutrality.  Mice were housed in single cages with free access to 
water and food at 30°C for a period of 10h. 
 
Locomotor Activity, Metabolic Rate, and Body Temperature.  Locomotor 
activity and metabolic rate was measured in 30 minute-intervals for the 
indicated time using a comprehensive laboratory animal monitoring system 
(CLAMS, Linton Instrumentation and Columbus Instruments) after 24h of 
acclimatization.  Mice had free access to food and water during the 
acclimatization period.  For the measurement period food was removed.  
Body temperature was measured using a rectal thermometer (BAT-12, 
Physitemp). 
 
Ex vivo Oxygen Consumption and Extracellular Acidification Rate.  
Oxygen consumption and extracellular acidification rate of BAT were 
measured using an XF24 extracellular flux analyzer (Seahorse Biosciences).  
Mice were housed in single cages at either 22°C or 4°C for 4h without food 
and subsequently BAT was collected and cut in approximately 0.5ug big 
pieces.  Tissues were washed 3 times with Seahorse assay buffer 
supplemented with 25mM glucose, 2mM glutamine, 1mM sodium pyruvate 
adjusted to pH 7.4.  Subsequently BAT pieces were placed in the center of a 
Seahorse XF24 islet capture microplate containing 675uL of Seahorse assay 
buffer.  After 30 minutes incubation at 37°C without CO2, oxygen consumption 
and extracellular acidification rate was measured 10 times and normalized to 
tissue weight. From each mouse 5 individual BAT pieces were used for 
measurement. 
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BAT Triglyceride and Free Fatty Acid Measurement.  For the free fatty acid 
measurement, the crude lipid fraction was extracted from BAT using 
choroform:methanol (2:1).  From this fraction the amount of free fatty acids 
was determined using a commercial kit (HR Series NEFA-HR(2)) and 
normalized to tissue weight.  For triglyceride measurement, the crude lipid 
fraction was further purified on a solid-phase extraction column (UPTI-CLEAN 
NH2-S 100mg/1mL SPE Colums, Interchim).  Subsequently amount of 
triglycerides was determined using a commercial kit (TG PAP BioMérieux) 
and normalized to tissue weight. 
 
RNA Isolation and RT-PCR. Total RNA from BAT or sWAT was isolated with 
TRIzol reagent (Sigma) and RNeasy kit (Qiagen) followed by cDNA synthesis 
using iScript cDNA synthesis kit (Bio-Rad).  Semi-quantitative real-time PCR 
analysis was performed using fast SYBR green (Applied Biosystems) on a 
StepOnePlus Real-Time PCR System (Applied Biosystems).  Relative 
expression levels were determined by normalizing to either RPL0 or TBP 
expression using the ΔΔCt method.  The sequence for the primers used in 
this study can be found in Supplementary Table 1. 
 
mtDNA Copy Number Determination.  Total DNA was isolated from BAT by 
incubating the tissue in PBND buffer containing 0.1mg Proteinase K at 57°C 
over night, followed by proteinase K inactivation at 95°C for 10 minutes.  DNA 
was subsequently purified using a standard chloroform/phenol/isoamyl alcohol 
precipitation.  mtDNA was determined in relation to the genomic DNA by qRT-
PCR using primers against the D-loop region for mtDNA and against the 
single-copy nuclear gene Ndufv1 for genomic DNA.  The sequence for the 
primers used can be found in Supplementary Table 1. 
 
Protein Isolation and Western Blot.  For norepinephrine or 8-Br-cAMP 
stimulation and subsequent Western Blot analysis in cells, cells were starved 
for 16h in DMEM supplemented with 1% FCS, 4.5g/L glucose and 2mM 
glutamine.  Cells were pre-treated for 30 minutes with DMSO, 100nM 
Rapamycin, 125nM Torin, 100nM Wortmannin, 10uM ESI-09, or for 2h with 
20uM H89 and subsequently stimulated with 3uM of norepinephrine for 2h or 
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1mM 8-Br-cAMP for 30min unless indicated otherwise.  Subsequently, cells 
were harvested in cold RIPA buffer containing 50mM Tris-HCl (pH 7.5), 2mM 
EDTA, 2mM EGTA, 150mM NaCl, 1% NP-40, 0.5% Na-Deoxycholate, 0.1% 
SDS, protease inhibitors (Roche) and phosphatase inhibitors (Sigma-Aldrich).  
For protein isolation from adipose tissue, tissue was homogenized in lysis 
buffer containing 100mM Tris-HCl (pH 7.5), 2mM EDTA, 2mM EGTA, 1% 
Triton X-100, protease inhibitors (Roche) and phosphatase inhibitors (Sigma-
Aldrich).  Protein concentration was determined by Bradford assay and equal 
amounts of protein were separated on SDS-PAGE followed by transfer onto a 
nitrocellulose membrane (Whatman).  The following antibodies were used to 
detect the proteins of interest: Akt (Cell Signaling, cs-4685), Akt-pS473 (Cell 
Signaling, cs-9271), Creb (Cell Signaling, cs-9196), Creb-pS133 (Cell 
Signaling, cs-9197), actin (Millipore, MAB1501), PKA (Cell Signaling, cs-
4782), PKA-pT192 (Cell Signaling, cs-4781), AMPK (Cell Signaling, cs-2532), 
AMPK-pT172 (Cell Signaling, cs-2535), raptor (Cell Signaling, cs-2280), 
raptor-pS792 (Cell Signaling, cs-2083), ACC (Cell Signaling, cs-3662), ACC-
pS79 (Cell Signaling, cs-3661), perilipin (Cell Signaling, cs-9349), perilipin-
pS497 (Vala Sciences, 4855), HSL (Cell Signaling, cs-4107), HSL-pS563 
(Cell Signaling, cs-4139), PKCα (Cell Signaling, cs-2056), PKCα-pS638/641 
(Cell Signaling, cs-9375), Mitoprofile (MitoSciences, MS604), HKI (Cell 
Signaling, cs-2024), HKII (Cell Signaling, cs-2867), GLUT1 (Abcam, ab-
40084), GLUT4 (Novus Biologicals, NBP2-22214), Na/K-ATPase (Cell 
Signaling, cs-3010), UCP1 (Abcam, ab-10983), GAPDH (Cell Signaling, cs-
2118), rictor (Cell Signaling, cs-2114). 
 
2-Deoxyglucose uptake.  For 2-DG uptake measurement in BAT, mice were 
housed in single cages at 22°C or 4°C for 4h without food.  Subsequently, 
mice were treated with 32.8ug/kg of 2-DG (Sigma) and sacrificed 45 minutes 
later.  BAT was harvested and lysed in 10mM Tris-HCl (pH 8.1).  2-DG uptake 
was measured by quantifying 2-DG6P accumulation in BAT using a 
commercial kit (Cosmo Bio Co, LTD.) following the manufacturer’s 
instructions.  Values were normalized to tissue weight. 
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Hexokinase activity.  Crude mitochondrial and cytosolic fractions were 
isolated from fresh BAT of mice that were housed in single cages at 22°C or 
4°C for 4h without food by differential centrifugation.  Hexokinase activity of 
the fractions was determined using a commercial kit (Abcam), following the 
manufacturer’s instructions.  Equal amount of protein was used for activity 
determination. 
 
Histology and Immunostainings.  Tissue was fixed over night in 4% 
paraformaldehyde in PBS at 4°C, dehydrated, embedded in paraffin and cut 
in 5um thick sections.  Sections were stained with H&E (Merck) to perform 
general histology.  For immunostainings the following antibody was used: 
RFP (ab62341, Abcam).  DAPI was used to stain nuclei. 
 
Electron Microscopy.  Tissue was fixed in 3% paraformaldehyde/0.5% 
glutaraldehyde, followed by fixation in 1% osmiumtetroxid and subsequent 
embedding in epon.  Tissue was cut in 60-70nm thick sections and images 
were taken with a Morgagni 268(D) TEM (FEI). 
 
Blood Analysis.  Free fatty acids and glycerol in plasma were determined 
using a commercial kit (HR Series NEFA-HR(2).  Plasma triglycerides were 
measured using a biochemical analyzer (Cobas c 111 analyzer, Roche). 
 
Recombinant AAV Vector Production and Delivery.  AAV vector 
production and delivery into BAT was carried out as described by Jimenez et 
al. (Jimenez et al. 2013).  Briefly, single-stranded AAV vectors were 
produced through triple transfection of HEK293 cells and subsequent 
purification on a CsCl gradient.  AAV vectors used were as follows: AAV8-
CAG-RFP, AAV8-CAG-humanAkt2S474D and AAV9-CMV-HKII.  Noncoding 
plasmids carrying the CAG or CMV promoter and a multicloning site (AAV8-
CAG-null, AAV9-CMV-null) were used to produce null particles.  For intra BAT 
AAV administration, mice were anaesthetized with isoflurane and a 
longitudinal incision was performed at the interscapular area to expose the 
BAT.  Each lobe of the BAT was injected twice with 10uL of viral solution to 
distribute the vector in the entire depot.  Each mouse received 2x1011 viral 
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genomes dissolved in 0.001% Pluronics in PBS.  Mice were allowed to 
recover from the surgery for 2 weeks before experiments were performed. 
 
Statistical Analysis.  All data are expressed as mean ± SEM. To determine 
statistically significant differences between groups, unpaired Student’s t-test 
was used. 
 
Results 
Norepinephrine activates mTORC2 in vitro via cAMP, PI3K and Epac1.  To 
investigate the role of mTORC2 signaling in NST, we first examined whether 
mTORC2 is activated by signals that induce thermogenesis.  In particular, 
differentiated brown adipocytes (dBACs) were treated with NE to induce β-
adrenergic signaling.  As expected, NE treatment resulted in stimulation of 
PKA signaling as suggested by increased Creb-S133, HSL-S563, and 
perilipin-S497 phosphorylation (Figure 1A).  Importantly, NE also stimulated 
phosphorylation of the mTORC2 target sites Akt-S473, -T450, and 
PKCα-S638/641 (Figure 1A).  We note that PKCα-S638/641 phosphorylation 
results in reduced turnover and thereby elevated levels of total 
PKCα (Ikenoue et al. 2008).  These observations suggest that β-adrenergic 
stimulation induces mTORC2 signaling, in addition to PKA, in dBACs. 
 Next, we investigated the pathway via which NE stimulates mTORC2.  
Insulin activates mTORC2 in a PI3K-dependent but mTORC1-independent 
manner.  We examined whether NE activates mTORC2 in a similar manner.  
We stimulated dBACs with NE in the presence of the pan-mTOR (mTORC1 
and mTORC2) inhibitor Torin, the mTORC1-specific inhibitor rapamycin or the 
PI3K inhibitor Wortmannin.  Similar to insulin-induced mTORC2 stimulation, 
NE-induced activation of mTORC2 was independent of mTORC1, since 
pretreatment of dBACs with rapamycin did not prevent induction of Akt-S473 
phosphorylation upon NE stimulation (Figure 1B).  In contrast, inhibition of 
mTOR with Torin or of PI3K with Wortmannin prevented Akt-S473 
phosphorylation (Figure 1B).  Hence, NE-induced activation of mTORC2 in 
dBACs is dependent on PI3K and independent on mTORC1. 
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NE stimulation leads to an increase in intracellular cAMP, which is 
crucial for NE-induced activation of PKA signaling (Cannon and Nedergaard 
2004).  To test whether cAMP is required for NE-induced activation of 
mTORC2, we treated dBACs with the cell-permeable cAMP analogue 8-Br-
cAMP.  Similar to NE stimulation, 8-Br-cAMP treatment induced Akt-S473 
phosphorylation in dBACs (Figure 1C).  8-Br-cAMP stimulated mTORC2 
signaling when mTORC1 was blocked with rapamycin, but was no longer able 
to induce Akt-S473 phosphorylation when mTOR or PI3K were inhibited with 
Torin or Wortmannin, respectively (Figure 1C).  Thus, NE induces mTORC2 
signaling via cAMP and PI3K.   
cAMP has several target proteins, two of which are PKA and Epac1. 
Epac1 mediates cAMP-induced activation of mTORC2 in prostate cancer cells 
(Misra and Pizzo 2012), and thus might be involved in cAMP-induced 
stimulation of mTORC2 in BAT.  To investigate whether PKA or Epac1 is 
required for cAMP-induced activation of mTORC2, we stimulated dBACs with 
8-Br-cAMP in the presence of the PKA inhibitor H89 or the Epac inhibitor ESI-
09.  Interestingly, treatment of dBACs with H89 resulted in a hyper-
phosphorylation of Akt-S473, suggesting that inhibition of PKA signaling does 
not impair activation of mTORC2 (Figure 1D).  In contrast, treatment with the 
Epac inhibitor ESI-09 prevented 8-Br-cAMP induced phosphorylation of Akt-
S473, suggesting that NE activates mTORC2 via cAMP, Epac1 and PI3K 
(Figure 1D). 
 
Norepinephrine and cold activate mTORC2 in vivo.  We next assessed 
whether NE stimulation can induce mTORC2 signaling in BAT in vivo.  In line 
with our in vitro results, treatment of mice with NE induced phosphorylation of 
the mTORC2 target Akt (Figure 2A).  Importantly, AdRiKO mice (Cybulski et 
al. 2009), which are defective for mTORC2 signaling in both BAT and white 
adipose tissue (WAT) (Supplementary Figure 1A), did not display induction 
of Akt-S473 phosphorylation in BAT upon NE stimulation (Figure 2B).  
Hence, functional mTORC2 is required for Akt phosphorylation in BAT in 
response to NE.  Since NE is released from the brain upon cold exposure, we 
hypothesized that mTORC2 signaling in BAT could also be induced by cold 
stress.  Similar to the results obtained with NE stimulation, cold exposure 
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induced Akt-S473 phosphorylation in BAT of control mice (Figure 2C).  Again, 
this induction was dependent on functional mTORC2 signaling as Akt 
phosphorylation and phosphorylation of the Akt target FoxO1 were not 
induced in BAT upon cold exposure of AdRiKO mice (Figure 2C).  In contrast 
to BAT, mTORC2 signaling was not induced in subcutaneous WAT (sWAT) 
upon cold exposure (Supplementary Figure 1B).  Taken together, these data 
demonstrate that mTORC2 signaling is induced by NE and cold in BAT but 
not in sWAT. 
As we observed an induction of mTORC2 signaling in BAT upon NE 
and cold stimulation, we next investigated whether a defect in mTORC2 
signaling affected temperature regulation.  AdRiKO mice were hypothermic 
when housed at 22°C, which is a mild temperature stress for mice (Figure 
2D).  The hypothermia could not be accounted for by a reduction in locomotor 
activity (Supplementary Figure 1C). In contrast, housing AdRiKO mice at 
thermoneutrality (30°C) for 10h, partially prevented this hypothermic 
phenotype (Figure 2E).  Next, we performed an acute cold exposure with 
AdRiKO and control mice.  In contrast to control mice, AdRiKO mice were 
unable to maintain stable body temperature when housed at 4°C (Figure 2F).  
Thus, inactivation of mTORC2 signaling in adipose tissue leads to decreased 
body temperature and increased sensitivity to cold stress. 
 
mTORC2 in adipose tissue is not required for cold-induced lipid droplet 
mobilization, mitochondrial uncoupling, and β-oxidation.  Thermogenesis 
upon β-adrenergic stimulation requires mobilization of lipid stores, induction of 
β-oxidation, and stimulation of mitochondrial uncoupling to generate heat.  
Since AdRiKO mice are hypothermic and exhibit increased sensitivity to cold 
(see above), we investigated whether AdRiKO mice are defective in lipid 
mobilization, β-oxidation or mitochondrial uncoupling in adipose tissue. There 
was no discernible difference in the morphology of lipid droplets in sWAT from 
AdRiKO mice compared to wild type control mice kept at 22°C.  Furthermore, 
both were able to mobilize sWAT lipid stores upon cold exposure (4°C) as 
suggested by a reduction in the size of lipid droplets, i.e., the appearance of 
multilocular adipocytes, in sWAT (Figure 3A).  In line with this, cold-exposed 
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AdRiKO and control mice also displayed a comparable increase in levels of 
circulating non-esterified fatty acids (NEFAs), i.e., free fatty acids, and 
glycerol (Figure 3B and 3C).  In BAT, however, AdRiKO mice housed at 22°C 
displayed larger lipid droplets compared to control mice (Figure 3D).  At 4°C, 
lipid droplet size in BAT decreased to the same extent in AdRiKO and control 
mice (Figure 3D), and free fatty acid levels were even enhanced in the 
AdRiKO BAT (Figure 3E).  These findings suggest that the defect in 
temperature regulation in AdRiKO mice is most likely not due to impaired 
release of free fatty acids in sWAT and BAT upon cold exposure. 
As mentioned above, cold-exposed AdRiKO mice display significantly 
increased levels of free fatty acids in BAT compared to control mice (Figure 
3E).  We hypothesized that this increase in NEFAs might be due to impaired 
mitochondrial function, which could lead to accumulation of NEFAs in BAT.  
To test this possibility, we first measured induction of genes involved in 
mitochondrial uncoupling in BAT upon cold exposure.  Despite the cold-
sensitive phenotype of AdRiKO mice, mRNA levels of UCP1, Dio2 and PGC-
1α were induced to a similar extent in BAT of AdRiKO and control mice 
(Figure 4A), and UCP1 protein levels were also similar (Figure 4B).  Second, 
AdRiKO mice did not exhibit any defect in expression of genes involved in β-
oxidation (Figure 4C).  Thus, AdRiKO mice appear normal for induction of the 
thermogenic transcriptional program and expression of β-oxidation genes.  
Third, we measured expression of mitochondrial proteins in BAT, in particular 
proteins of the electron transport chain - the so-called mitoprofile.  AdRiKO 
mice displayed a slight decrease (22°C) or no change (4°C) in their mitoprofile 
compared to control mice (Figure 4D).  Fourth, mitochondrial DNA (mtDNA) 
copy number was unchanged in BAT of AdRiKO mice (Figure 4E), 
suggesting that BAT of AdRiKO and control mice contain a similar amount of 
mitochondria.  Fifth, EM micrographs of BAT revealed no difference between 
AdRiKO and control mitochondria with regard to size, shape and cristae 
structure (Figure 4F).  Finally, cold-exposed AdRiKO mice exhibited normal 
induction of oxygen consumption in BAT (Figure 4G) and at the whole body 
level (Figure 4H).  Thus, BAT in AdRiKO mice has normal mitochondrial 
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function, suggesting that the observed cold sensitivity of AdRiKO mice does 
not stem from a mitochondrial defect. ,  
Despite a similar maximal induction of whole-body respiration (Figure 
4H), AdRiKO mice were unable to maintain an enhanced metabolic rate 
throughout the duration of the cold exposure time course (Figure 4I).  This 
inability to maintain an enhanced metabolic rate may account for the inability 
of AdRiKO mice to sustain an NST response. 
 
mTORC2 in adipose tissue is required for cold-induced glucose uptake 
and glycolysis.  Glucose uptake and glycolysis are strongly enhanced in 
BAT upon cold exposure, to compensate for the loss of mitochondrial ATP 
production due to heat-generating mitochondrial uncoupling (Greco-Perotto 
et al. 1987, Vallerand et al. 1990, Hao et al. 2015).  mTORC2 is an 
important regulator of insulin-induced glucose uptake and glycolysis in WAT, 
muscle and liver (Kumar et al. 2008, Kumar et al. 2010, Hagiwara et al. 
2012).  Thus, reduced glucose uptake and glycolysis might explain the failure 
of AdRiKO mice to maintain an enhanced metabolic rate upon cold exposure 
(Figure 4I).  To test this notion, we examined cold-induced glucose uptake in 
BAT.  More specifically, we measured 2-deoxyglucose-6-phosphate (2DG6P) 
accumulation in BAT 45 minutes after injecting mice with 2-deoxyglucose 
(2DG).  BAT in AdRiKO mice displayed significantly impaired glucose uptake 
upon cold exposure (Figure 5A).  Similarly, cold exposed AdRiKO mice failed 
to increase glycolysis in BAT, as indicated by a reduced extracellular 
acidification rate (ECAR) by BAT explants (Figure 5B).  Thus, mTORC2 
signaling is required to induce glucose uptake and glycolysis in BAT upon 
cold exposure.  To determine whether absence of mTORC2 in BAT leads to 
energetic stress upon cold exposure, which could account for an inability to 
sustain NST, we examined AMP-activated protein kinase (AMPK) signaling.  
AMPK is activated in response to low energy levels (Hardie and Hawley 
2001).  Indeed, AdRiKO mice displayed enhanced phosphorylation of AMPK-
T172 and phosphorylation of the AMPK targets ACC and raptor (Figure 5C), 
indicating energy stress in BAT of these mice. 
 Next, we investigated how mTORC2 signaling affects glucose uptake 
and glycolysis in BAT.  mTORC2 signaling has been shown to mediate 
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insulin-stimulated translocation of GLUT4 to the plasma membrane (Kumar et 
al. 2010).  Moreover, GLUT1 is involved in glucose uptake into brown 
adipocytes upon β-adrenergic stimulation (Dallner et al. 2006).  To test 
whether mTORC2 signaling in BAT affects plasma membrane localization of 
GLUT1 or GLUT4, we isolated plasma membrane from AdRiKO and control 
BAT.  The amount of GLUT1 and GLUT4 in the two plasma membrane 
fractions was similar (Figure 5D).  This suggests that mTORC2 in BAT does 
not mediate cold-induced glucose uptake and glycolysis by affecting 
localization of glucose transporters.  Glucose uptake is also affected by 
hexokinases, which phosphorylate glucose to catalyze the first and rate-
limiting step of glycolysis.  From the four different hexokinase isoforms, 
hexokinase I (HKI) and hexokinase II (HKII) are the two dominant isoforms in 
BAT, and are found both in the cytosol and at mitochondria (Shinohara et al. 
1998, Wilson 2003).  Immunoblot analysis of cytosolic (Figure 5E) and 
mitochondrial (Figure 5F) fractions from BAT of AdRiKO and control mice 
revealed no significant difference in the amount and subcellular localization of 
HKI and HKII.  However, while mitochondrial hexokinase activity was similar 
in AdRiKO and control mice, cytosolic hexokinase activity was induced in BAT 
of cold-exposed control but not AdRiKO mice (Figure 5G and 5H).  Thus, 
mTORC2 signaling in BAT stimulates glucose uptake and glycolysis upon 
cold exposure via regulation of cytosolic hexokinase activity.  Collectively, the 
above findings suggest that impaired glucose metabolism in BAT of AdRiKO 
mice accounts for the failure to sustain NST.  
 
Restoration of glucose uptake or Akt signaling suppresses the 
thermogenic defect in AdRiKO mice.  Our data suggest that AdRiKO mice 
are hypothermic and sensitive to cold exposure due to impaired activation of 
glucose metabolism in BAT.  We therefore reasoned that restoring glucose 
uptake in BAT could be sufficient to improve temperature regulation.  To test 
this notion, we overexpressed HKII in BAT of AdRiKO and control mice via 
intra-BAT injection of an adeno-associated virus (AAV) expressing HKII.  This 
technique was used previously to activate glucose uptake specifically in BAT 
(Jimenez et al. 2013).  To confirm that the transgene was specifically 
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targeted to BAT, we injected an RFP-expressing AAV into the BAT of control 
mice and measured RFP expression.  RFP was strongly expressed in BAT, 
slightly expressed in liver, and not detected in other tissues (Supplementary 
Figure 2A and 2B).  Intra-BAT injection of an HKII-expressing AAV resulted 
in a strong increase in HKII mRNA levels in BAT of both AdRiKO and control 
mice (Figure 6A).  Overexpression of HKII enhanced cold-induced glucose 
uptake in BAT of both AdRiKO and control mice (Figure 6B).  Importantly, 
restoration of glucose uptake suppressed the hypothermic phenotype (Figure 
6C) and improved cold tolerance (Figure 6D) in AdRiKO mice.  Thus, 
restoration of glucose metabolism in BAT of AdRiKO mice is sufficient to 
reverse the hypothermic and cold sensitive phenotype caused by inactivation 
of mTORC2. 
 Next we investigated how mTORC2 regulates glucose metabolism and 
temperature homeostasis in BAT.  Akt is a major downstream effector of 
mTORC2 and stimulates glucose uptake in skeletal muscle and liver 
downstream (Kumar et al. 2008, Hagiwara et al. 2012).  Furthermore, Akt 
signaling is activated in BAT upon cold exposure (Figure 2C).  Thus, we 
investigated whether expression of constitutively active Akt2 (Akt2S474D) 
(Hagiwara et al. 2012) in BAT of AdRiKO mice could restore glucose uptake 
and temperature regulation.  To this end, we injected AAV expressing 
Akt2S474D into BAT of AdRiKO and control mice.  This resulted in a strong 
expression of Akt2S474D in BAT of AdRiKO and control mice, while PKCα and 
PKCα-p638/641 levels were unchanged (Figure 6E).  Introduction of 
Akt2S474D increased body temperature and improved cold tolerance in AdRiKO 
mice (Figure 6F and 6G).  Thus, restoration of Akt activity in BAT of AdRiKO 
mice improved temperature homeostasis.  To investigate whether restoration 
of Akt activity also suppressed the observed defects in glucose metabolism, 
we measured cold-induced glucose uptake in BAT of AdRiKO and control 
mice.  Interestingly, cold-induced glucose uptake was restored to control 
levels in BAT of AdRiKO mice expressing Akt2S474D (Figure 6H).  In 
conclusion, these findings suggest that mTORC2-Akt signaling regulates BAT 
glucose metabolism and thereby NST. 
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Discussion 
We investigated the role of mTORC2 signaling in the regulation of 
thermogenesis and cold-induced glucose uptake.  We show that mTORC2 
signaling is activated in brown adipocytes in vitro and in vivo upon NE-
stimulation and cold exposure via cAMP and Epac1, independently of PKA 
signaling.  We also demonstrate that mTORC2-Akt signaling in BAT mediates 
cold-induced glucose uptake and glycolysis, and is thereby sustains NST. 
 We found that mice with inactive mTORC2 signaling in adipose tissue 
(AdRiKO mice) fail to maintain a metabolic rate required to sustain NST and 
are thus hypothermic and sensitive to cold stress.  This impaired NST 
response of AdRiKO mice is most likely due to impaired glucose uptake and 
glycolysis in BAT, which results in the inability to maintain energy 
homeostasis under cold stress.  Importantly, overexpressing HKII restored 
glucose uptake and glycolysis in BAT, and thereby restored body temperature 
and improved cold tolerance.  These results reveal the importance of glucose 
metabolism, and its regulation by mTORC2, in the maintenance of NST.  
Interestingly, Olsen et al. reported that β-adrenergic stimulation induced 
glucose uptake in brown adipocytes in vitro in an mTORC2-dependent 
manner (Olsen et al. 2014).  Furthermore, the authors reported that mTORC2 
promotes glucose uptake by stimulating GLUT1 translocation to the plasma 
membrane in an Akt-independent fashion (Olsen et al. 2014).  In contrast to 
these in vitro results, we did not observe a change in GLUT1 plasma 
membrane localization in BAT of AdRiKO mice.  Moreover, our in vivo results 
show that mTORC2 mediates cold-stimulated glucose uptake and glycolysis 
in an Akt-dependent manner.  AdRiKO mice displayed a strong decrease in 
Akt S473 phosphorylation in BAT and overexpression of a constitutively active 
Akt2 mutant (Akt2S474D) restored glucose uptake, body temperature and 
increased cold tolerance in AdRiKO mice.  The mechanism by which 
mTORC2 regulates glucose uptake might be different in vivo and in vitro.  
 How does mTORC2-Akt signaling in BAT stimulate glucose uptake and 
glycolysis?  We found that AdRiKO mice are defective for induction of 
cytosolic hexokinase activity in BAT upon cold exposure, whereas 
mitochondrial hexokinase activity was unaffected.  Interestingly, it has been 
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proposed that mitochondria-associated hexokinase utilizes ATP generated by 
the mitochondria for glucose phosphorylation (Wilson 2003).  However, upon 
cold stress, mitochondrial ATP production is strongly reduced due to 
activation of the uncoupling protein UCP1 (Lindberg et al. 1967, De Meis et 
al. 2012).  Thus, in the context of thermogenesis, cytosolic rather than 
mitochondrial hexokinase may account for the increase in glucose uptake and 
glycolytic rate.  In summary, our data suggest that mTORC2 in BAT 
specifically activates cytosolic hexokinase, which is in turn required for cold-
induced glucose uptake and glycolysis and maintenance of energy 
homeostasis upon cold stress.  Future studies should address the mechanism 
by which mTORC2-Akt signaling activates cytosolic hexokinase. 
 We observed that mTORC2 signaling is activated in brown adipocytes 
upon β-adrenergic stimulation.  Similar to insulin-induced activation of 
mTORC2, we found that β-adrenergic stimulation activates mTORC2 in a 
PI3K-dependent and mTORC1-independent fashion.  Additionally, we found 
that β-adrenergic signaling stimulates mTORC2 via cAMP and Epac1, 
independently of PKA signaling.  Interestingly, it has been shown previously 
that mTORC2 signaling is activated in prostate cancer cells in an Epac1-
dependent fashion upon cAMP-stimulation (Misra and Pizzo 2012).  Thus, 
induction of mTORC2 signaling upon β-adrenergic stimulation seems to occur 
in several distinct cell types and could thus represent another major input for 
mTORC2 activation in addition to growth factors.  Our results also suggest 
that mTORC2-Akt signaling in addition to PKA signaling plays an important 
role in the NST response.  
 Loss of mTORC2 impaired temperature homeostasis, but without 
affecting cold-induced β-oxidation, lipid mobilization and mitochondrial 
uncoupling.  This is in contrast to the study of Hung et al., which found that 
Myf5 muscle- and BAT progenitor cell-specific rictor KO (Myf5-rictor KO) mice 
display increased oxidative metabolism and uncoupling in BAT (Hung et al. 
2014).  A possible explanation for these seemingly discrepant results could be 
that Hung et al. used a Myf5-driven Cre recombinase to delete rictor at the 
preadipocyte stage, whereas we used an aP2-driven Cre recombinase to 
delete rictor only in mature adipocytes.  A defect in mTORC2 signaling during 
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adipogenesis could affect mature BAT function and potentially result in 
changes in oxidative metabolism.  Nevertheless, our results demonstrate that 
inactivation of mTORC2 signaling in mature adipocytes does not affect lipid 
mobilization, mitochondrial function or oxidative metabolism in BAT. 
 Taken together, our results demonstrate a novel role for mTORC2 in 
BAT in the regulation of energy homeostasis and thermogenesis, through Akt-
mediated stimulation of glucose uptake and glycolysis.  NST and subsequent 
energy dissipation has been proposed as a novel strategy to treat obesity and 
decrease the risk of obesity-associated diseases (Clapham and Arch 2011).  
Additionally, cold-stimulated glucose uptake could be used to normalize blood 
glucose levels in insulin resistant diabetic patients.  Our data suggest that 
activation mTORC2 in BAT, to stimulate glucose metabolism, could have 
synergistic effects with NST activators in the treatment of obesity. 
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Figure 1.  NE activates mTORC2 in vitro via cAMP, PI3K and Epac1. (A) 
Immunoblot analysis of BAT cells stimulated with norepinephrine (NE) for the 
indicated proteins.  (B) Immunoblot analysis of BAT cells stimulated with NE 
in the presence of Rapamycin (Rapa), Torin or Wortmannin (Wrtm) for the 
indicated proteins.  (C) Immunoblot analysis of BAT cells stimulated with 8-Br-
cAMP in the presence of Rapa, Torin or Wrtm for the indicated proteins.  (D) 
Immunoblot analysis of BAT cells stimulated with 8-Br-cAMP in the presence 
of Wrtm, H89 or ESI-09 for the indicated proteins. 
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Figure 2.  NE and cold activate mTORC2 in vivo.  (A) Immunoblot analysis of 
BAT from control mice treated with either norepinephrine (NE) or vehicle for 
the indicated proteins.  (B) Immunoblot analysis of BAT from AdRiKO and 
control mice treated with either norepinephrine (NE) or vehicle for the 
indicated proteins.  (C) Immunoblot analysis of BAT from AdRiKO and control 
mice housed at either 22°C or 4°C for the indicated proteins.  (D) Body 
temperature of AdRiKO and control mice housed at 22°C.  (E) Body 
temperature of AdRiKO and control mice housed at 22°C or 30°C.  (F) Body 
temperature loss upon cold exposure of AdRiKO and control mice.  Data 
represent mean ± SEM.  Statistically significant differences between AdRiKO 
and control mice are indicated with asterisks (*=p<0.05; **=p<0.01, 
***=p<0.001).  Statistically significant differences between temperatures are 
indicated with a number sign (#=p<0.05; ##=p<0.01; ###=p<0.001). 
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Figure 3.  mTORC2 in adipose tissue is not required for cold-induced lipid 
droplet mobilization.  (A) H&E staining of sWAT sections from AdRiKO and 
control mice.  (B) Non-esterified fatty acids (NEFAs) in plasma of AdRiKO and 
control mice.  (C) Glycerol in plasma of AdRiKO and control mice.  (D) H&E 
staining of BAT sections from AdRiKO and control mice.  (E) NEFAs in BAT of 
AdRiKO and control mice.  Data represent mean ± SEM.  Statistically 
significant differences between AdRiKO and control mice are indicated with 
asterisks (*=p<0.05; **=p<0.01, ***=p<0.001).  Statistically significant 
differences between temperatures are indicated with a number sign 
(#=p<0.05; ##=p<0.01; ###=p<0.001). 
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Figure 4.  mTORC2 in adipose tissue is not required for cold-induced 
mitochondrial uncoupling and β-oxidation 
  (A) mRNA levels of the indicated genes in BAT of AdRiKO and control mice. 
(B) Immunoblot analysis of BAT from AdRiKO and control mice for the 
indicated proteins.  (C) mRNA levels of the indicated genes in BAT of AdRiKO 
and control mice.  (D) Immunoblot analysis of BAT from AdRiKO and control 
mice for the indicated proteins.  (E) Mitochondrial DNA content of BAT from 
AdRiKO and control mice (F) Electronmicrographs of BAT from AdRiKO and 
control mice.  (G) Oxygen consumption rate (OCR) of BAT explants from 
AdRiKO and control mice.  (H) Maximal respiration (VO2 max) of AdRiKO and 
control mice.  (I) Respiration (VO2) of AdRiKO and control mice upon cold 
exposure.  Data represent mean ± SEM.  Statistically significant differences 
between AdRiKO and control mice are indicated with asterisks (*=p<0.05; 
**=p<0.01, ***=p<0.001).  Statistically significant differences between 
temperatures are indicated with a number sign (#=p<0.05; ##=p<0.01; 
###=p<0.001). 
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Figure 5.  mTORC2 in adipose tissue is required for cold-induced glucose 
uptake and glycolysis (A) 2-Deoxyglucose-6-phosphate (2DG6P) 
accumulation in BAT of AdRiKO and control mice.  (B) Extracellular 
acidification rate (ECAR) of BAT explants from AdRiKO and control mice.  (C) 
Immunoblot analysis of BAT from AdRiKO and control mice for the indicated 
proteins. (D) Immunoblot analysis of isolated plasma membranes from BAT of 
AdRiKO and control mice for the indicated proteins.  (E) Immunoblot analysis 
of cytosolic fractions from BAT of AdRiKO and control mice for the indicated 
proteins.  (F) Immunoblot analysis of crude mitochondrial fractions from BAT 
of AdRiKO and control mice for the indicated proteins.  (G) Cytosolic 
hexokinase activity in BAT of AdRiKO and control mice.  (H) Mitochondrial 
hexokinase activity in BAT of AdRiKO and control mice.  Data represent mean 
± SEM.  Statistically significant differences between AdRiKO and control mice 
are indicated with asterisks (*=p<0.05; **=p<0.01, ***=p<0.001).  Statistically 
significant differences between temperatures are indicated with a number sign 
(#=p<0.05; ##=p<0.01; ###=p<0.001). 
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Figure 6.  Restoration of glucose uptake or Akt signaling suppresses the 
thermogenic defect in AdRiKO mice.  (A) HKII mRNA expression level in BAT 
of AdRiKO and control mice infected with either AAV9-HKII or AAV9-empty.  
(B) Cold-induced 2-Deoxyglucose-6-phosphate (2DG6P) accumulation in BAT 
of AdRiKO and control mice infected with either AAV9-HKII or AAV9-empty.  
(C) Body temperature of AdRiKO and control mice infected with either AAV9-
HKII or AAV9-empty.  (D) Body temperature upon cold exposure of AdRiKO 
and control mice infected with either AAV9-HKII or AAV9-empty. (E) 
Immunoblot analysis of BAT from AdRiKO and control mice infected with 
either AAV8-Akt2S474D or AAV8-empty.  (F) Body temperature of AdRiKO and 
control mice infected with either AAV8-Akt2S474D or AAV8-empty.  (G) Body 
temperature upon cold exposure of AdRiKO and control mice infected with 
either AAV8-Akt2S474D or AAV8-empty.  (H) Cold-induced 2-Deoxyglucose-6-
phosphate (2DG6P) accumulation in BAT of AdRiKO and control mice 
infected with either AAV8-Akt2S474D or AAV8-empty.  Data represent mean ± 
SEM.  Statistically significant differences between AdRiKO and control mice 
are indicated with asterisks (*=p<0.05; **=p<0.01, ***=p<0.001).  Statistically 
significant differences between viruses are indicated with a number sign 
(#=p<0.05; ##=p<0.01; ###=p<0.001). 
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Supplementary Figure 1, Related to Figure 2.  Cold does not activate 
mTORC2 in sWAT. (A) Immunoblot analysis of BAT and sWAT of AdRiKO 
and control mice for the indicated proteins.  (B) Immunoblot analysis of sWAT 
of AdRiKO and control mice for the indicated proteins.  (C) Locomotor activity 
of AdRiKO and control mice.  Data represent mean ± SEM.  Statistically 
significant differences between AdRiKO and control mice are indicated with 
asterisks (*=p<0.05; **=p<0.01, ***=p<0.001). 
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Supplementary Figure 2, Related to Figure 6.  Intra-BAT injection targets 
genes of interest specifically to BAT.  (A) Immunostainings for RFP of BAT 
from control mice infected with either AAV8-RFP or AAV8-empty.  (B) RFP 
mRNA expression in BAT, liver, quadriceps, and WAT of control mice infected 
with either AAV8-RFP or AAV8-empty.  Data represent mean ± SEM. 
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Supplementary Table 1. Primer sequences used for qRT-PCR 
 
 
Target  forward primer (5’-3’) reverse primer (5’-3’) 
CACT CTGCGCCCATCATTGGA CAGACCAAACCCAAAGAAGCA 
CPT-1β  ATCATGTATCGCCGCAAACT CCATCTGGTAGGAGCACATGG 
Dio2 GAGGAAGGAAGAAGAGGAAGCAA TTCTTCCAGTGTTTTGGACA TGC 
E-loop GGTTCTTACTTCAGGGCCATCA GATTAGACCCGTTACCATCGAGAT 
HKII AAAACCAAGTGCAGAAGGTTGAC GAACCGCCTAGAAATCTCCAGAA 
LCAD CCAGCTAATGCCTTACTTGGAGA GCAATTAAGAGCCTTTCCTGTGG 
Ndufv1 CTTCCCCACTGGCCTCAAG CCAAAACCCAGTGATCCAGC 
PGC-1α  GAGAATGAGGCAAACTTGCTAGCG TGCATGGTTCTGAGTGCTAAGACC  
RFP GCGGCCACTACACCTGCGAC TCGGCGTGCTCGTACTGCTC 
RPL0 CTGCTGAACATGCTGAACATCTC CTTCAGGGTTATAAATGCTGCCG 
TBP TGCTGTTGGTGATTGTTGGT CTGGCTTGTGTGGGAAAGAT 
UCP1 TGATGAAGTCCAGACAGACAGTG TTATTCGTGGTCTCCCAGCATAG 
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4. Discussion and outlook 
 
The aim of this thesis was to gain a better understanding of how mTOR 
signaling in different metabolic organs regulates whole body metabolism.  To 
this end, we studied mTORC1 signaling in orexigenic neurons in the 
hypothalamus and mTORC2 signaling in adipose tissue to understand their 
role in the regulation of systemic energy homeostasis. 
 
 In the first part of this thesis, we studied the effects of mTORC1 
inactivation in orexigenic Agrp neurons on feeding behavior and systemic 
energy metabolism.  It has been previously shown that hypothalamic 
mTORC1 is involved in the regulation of feeding behavior and energy 
homeostasis.  For example, hyper-activation of mTORC1 in POMC neurons 
results in hyperphagia-induced obesity (Mori et al. 2009) and mTORC1 
signaling in the ARC is sensitive to the feeding state (Cota et al. 2006).  In 
line with previous findings (Cota et al. 2006), we observed that mTORC1 
activity in the ARC was induced by feeding and down-regulated by fasting.   
Moreover, we found that mTORC1 signaling in the ARC was circadian, 
displaying the highest intensity at ZT18, which corresponds to the active 
feeding period of the mice.  This finding is in agreement with other studies, 
showing that mTORC1 signaling activity displays a circadian pattern in 
several organs (Cao et al. 2011, Jouffe et al. 2013, Cornu et al. 2014, 
Khapre et al. 2014).  
Interestingly, we found that also Agrp and NPY mRNA expression was 
circadian, showing the highest expression at ZT18.  Since the circadian Agrp 
and NPY expression pattern matched the circadian mTORC1 activity, we 
hypothesized that mTORC1 signaling in Agrp neurons regulates Agrp and 
NPY expression.  Indeed, Agrp-raptor KO mice, which have no mTORC1 
activity in Agrp neurons, exhibited no circadian oscillation of Agrp and NPY 
expression.  Instead, Agrp and NPY levels were constitutively reduced.  
These data strongly suggest that mTORC1 signaling in Agrp neurons 
regulates circadian oscillation of Agrp and NPY levels either via a direct or an 
indirect mechanism.  However, despite low Agrp and NPY levels, Agrp-raptor 
KO mice consumed an equal amount of food compared to control mice.  
Dissertation - mTOR signaling in organismal energetics 
	   104 
Interestingly, several studies have shown that inhibition of Agrp or NPY 
expression does not affect feeding behavior in mice (Erickson et al. 1996, 
Marsh et al. 1998, Palmiter et al. 1998, Qian et al. 2002). These findings 
could thus explain why Agrp-raptor KO mice display a similar food intake 
compared to control mice despite low levels of Agrp and NPY.  Moreover, 
Agrp-raptor KO mice were able to induce Agrp and NPY expression after 
overnight starvation even though basal Agrp and NPY levels were low and the 
circadian oscillation of these orexigenic neuropeptides was absent in these 
mice.  Based on these findings, we suggest that circadian- and starvation-
induced expression of orexigenic neuropeptides is regulated by two distinct 
mechanisms.  While the circadian Agrp and NPY expression is mTORC1-
dependent, the starvation-induced expression of orexigenic neuropeptides is 
mTORC1-independent.  Interestingly, this is in line with our finding that 
mTORC1 signaling is inactive in the ARC after overnight starvation.  Hence, 
mTORC1 signaling is unlikely to mediate the starvation-induced increase in 
orexigenic neuropeptide expression and Agrp-raptor KO mice therefore 
display a normal induction of orexigenic neuropeptide expression upon 
starvation. 
What are the mechanisms that regulate circadian- and starvation-
induced expression of Agrp and NPY?  It has been proposed that insulin 
inhibits Agrp expression via activation of Akt and subsequent nuclear 
exclusion and inactivation of FoxO1 (Plum et al. 2006).  Upon starvation, Akt 
activity is low, resulting in activation of FoxO1 and subsequent stimulation of 
Agrp expression. Thus, absence of insulin could be a potential mechanism to 
induce Agrp expression in a fasted state.  However, in Agrp-raptor KO mice, 
Akt signaling is constantly hyper-activated due to absence of the negative 
feedback loop from S6K to IRS-1 (Harrington et al. 2004, Shah et al. 2004, 
Um et al. 2004, Harrington et al. 2005).  If the Akt/FoxO1 pathway described 
above was the main regulator of Agrp expression, Agrp expression would be 
constantly repressed in Agrp-raptor KO mice.  Contrarily, Agrp-raptor KO mice 
displayed a significant induction of Agrp expression upon starvation, which 
suggests that there is an Akt/FoxO1-independent signaling pathway that 
stimulates Agrp expression upon starvation. 
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It is also unlikely that insulin/Akt/FoxO1 signaling regulates the 
circadian expression pattern of Agrp and NPY.  In mice, circulating insulin 
levels are low during the light phase and increase during the dark phase.  If 
the insulin/Akt/FoxO1 pathway were the main regulator of circadian Agrp 
expression, the levels of orexigenic neuropeptides would be low during the 
dark phase, since insulin represses the action of FoxO1 on Agrp transcription 
(Matsuzaki et al. 2003).  In contrast to this, we found that Agrp and NPY 
expression was highest during the dark phase.  Hence, our observation 
suggests that the circadian expression pattern of Agrp and NPY is positively 
regulated by anabolic signaling.  Moreover, since Agrp-raptor KO mice failed 
to show a circadian oscillation of Agrp and NPY expression, mTORC1 might 
be a direct regulator of circadian orexigenic neuropeptide expression.  Future 
studies should be aimed at identifying the transcription factors that regulate 
the circadian- and starvation-induced orexigenic neuropeptide expression.  
This could for example be achieved through reverse chromatin 
immunoprecipitaion (ChIP) (Dejardin and Kingston 2009).  IP of the Agrp or 
NPY promoter regions followed by Mass Spectrometry allows the 
identification of proteins associated with these promoters.  Analysis of the 
bound proteins at different times of the day or in different feeding states could 
reveal novel transcription factors that mediate circadian- and fasting-induced 
orexigenic neuropeptide expression.  Interestingly, the Champion ChIP 
Transcription Factor Search Portal (SABiosciences) predicted binding sites for 
SREBP-1c and c-Myc within the Agrp and NPY promoter.  These transcription 
factors are downstream targets of mTORC1 signaling (West et al. 1998, 
Duvel et al. 2010).  Thus, mTORC1 might stimulate orexigenic neuropeptide 
expression via SREBP-1c and/or c-Myc. 
Analysis of the systemic metabolic phenotype of Agrp-raptor KO mice 
revealed that on a normal and on a high fat diet, Agrp-raptor KO mice did not 
display any difference in body weight, metabolic rate and feeding behavior 
compared to control mice.  Hence, this demonstrates that mTORC1 signaling 
in Agrp neurons is dispensable for the regulation of feeding behavior and 
energy homeostasis.  This observation is in line with a recent study showing 
that hyper-activation of mTORC1 in Agrp neurons did not cause any 
metabolic alterations (Yang et al. 2012).  In contrast to this, as mentioned 
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earlier, hyper-activation of mTORC1 in POMC neurons resulted in 
hyperphagic and obese mice (Mori et al. 2009). Interestingly, a similar 
observation has been made for mTORC2:  While specific deletion of rictor in 
POMC neurons caused abnormal feeding behavior, resulting in obesity; Agrp 
neuron-specific inactivation of mTORC2 did not lead to any metabolic 
alterations (Kocalis et al. 2014).  These findings suggest that mTORC1 and 
mTORC2 signaling are important for POMC neuronal function while they are 
dispensable for Agrp neuronal function.  Alternatively, compensatory 
mechanisms could have developed in the mice with Agrp neuron-specific 
alterations in mTOR signaling, circumventing the dependence on mTOR in 
Agrp neurons for the regulation of feeding behavior and energy homeostasis.  
In line with this hypothesis, ablation of Agrp neurons in neonatal mice does 
not result in any alterations in feeding behavior and energy metabolism.  
Contrariwise, deletion of Agrp neurons in adult mice results in a strong 
decrease in food intake leading to death due to starvation (Luquet et al. 
2005).  Thus, using an inducible Agrp-Cre line would allow modulation of 
mTOR signaling in Agrp neurons in adult mice.  This would circumvent the 
development of possible compensatory regulations and could help answer the 
question whether  mTOR signaling affects Agrp neuronal function. 
Taken together, characterization of Agrp-raptor KO mice revealed that 
mTORC1 signaling in Agrp neurons regulates circadian but not starvation-
induced expression of orexigenic neuropeptides without affecting feeding 
behavior and systemic energy homeostasis.  However, due to the possibility 
that compensatory mechanisms could have masked the effect of raptor 
deletion on Agrp neuronal function, it cannot be excluded that mTORC1 
signaling in Agrp neurons nevertheless could play a role in the regulation of 
energy homeostasis and feeding behavior. 
 
In the second part of this thesis we investigated the role of adipose 
mTORC2 signaling in non-shivering thermogenesis (NST).  NST-induced 
energy dissipation and glucose uptake is a promising strategy to induce 
weight loss in obese subjects and to normalize blood glucose levels in insulin-
resistant diabetic patients (Clapham and Arch 2011).  Identification of novel 
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regulators involved in NST and cold-induced glucose uptake could thus help 
develop new treatment options for patients with metabolic disorders.  
It is well established that mTORC2 signaling is crucial for insulin-
stimulated glucose uptake and glycolysis in skeletal muscle, liver and WAT 
(Kumar et al. 2008, Kumar et al. 2010, Hagiwara et al. 2012).  Moreover, 
mTORC2 signaling is also involved in the regulation of lipid metabolism 
(Hagiwara et al. 2012).  We therefore hypothesized that mTORC2 in BAT 
might be involved in the regulation of NST and/or cold-induced glucose 
uptake. 
Upon cold stress, NST is induced in BAT via NE-mediated stimulation 
of β-adrenergic receptors.  Interestingly, we found that mTORC2 was 
activated by β-adrenergic stimulation in brown adipocytes in vitro and in vivo.  
Similar to insulin-mediated stimulation of mTORC2, we demonstrated that β-
adrenergic activation of mTORC2 was dependent on PI3K.  Hence, these 
findings imply that both growth factor- and β-adrenergic signaling converge on 
PI3K to activate mTORC2.  How does β-adrenergic signaling activate PI3K?  
Our results suggest that the increase in intracellular cAMP upon β-adrenergic 
stimulation leads to activation of PI3K-mTORC2 signaling, since treatment of 
dBACs with 8-Br-cAMP stimulated mTORC2 activity.  Surprisingly, we found 
that the cAMP-mediated stimulation of mTORC2 was independent of the 
cAMP-dependent protein kinase PKA.  Instead, we demonstrated that NE 
activates mTORC2 in brown adipocytes via cAMP-mediated stimulation of 
Epac1.  Interestingly, in line with our findings in brown adipocytes, it has 
previously been shown that cAMP activates mTORC2 via Epac1 in prostate 
cancer cells (Misra and Pizzo 2012).  Moreover, Epac1 was shown to 
stimulate mTORC2 by activating PI3K (Mei et al. 2002).  Collectively, these 
and our findings imply that β-adrenergic stimulation activates mTORC2 in 
several distinct cell types and could thus constitute a novel major input for 
mTORC2 signaling besides growth factors.  In light of this, it would be 
interesting to identify additional cell types where mTORC2-signaling is 
activated in response to β-adrenergic stimulation.  Moreover, it would also be 
important to identify the physiological contexts under which such stimulation 
occurred.  For instance, β-adrenergic signaling in skeletal muscle and heart is 
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involved in the regulation of muscle mass, fiber type and contractility 
(Madamanchi 2007, Lynch and Ryall 2008).  β-adrenergic stimulation-
induced activation of mTORC2 could therefore also play an important role for 
heart and skeletal muscle function. 
Interestingly, in analogy with our findings for mTORC2, we observed 
that mTORC1 signaling was induced with NE and cAMP stimulation in dBACs 
in vitro and with NE and cold in BAT in vivo (Figures 1A-D). 
 
 
 
 
 
 
  
 
While activation of mTORC2 by NE and cAMP was dependent on PI3K, 
inhibition of PI3K did not prevent NE- and cAMP-induced stimulation of 
mTORC1 (Figures 1A and 1B).  However, mTORC1 activation by cAMP-
stimulation was impaired when PKA was inhibited with H89 (Figure 1B), 
suggesting that NE and cAMP activate mTORC1 in a PKA-dependent but 
PI3K-independent manner. Interestingly, it was shown in a recent study that 
mice with hyperactive PKA signaling in adrenal cortex display increased 
mTORC1 activity in adrenal cortical cells (de Joussineau et al. 2014).  This 
A B 
C D 
Figure 1. mTORC1 is activated by β-adrenergic signaling in brown adipocytes in vitro and 
in vivo.  (A) Immunoblot analysis of dBACs after NE stimulation in the presence of DMSO, 
Rapamycin (Rapa), Torin, or Wortmannin (Wrtm.) for the indicated antibodies.  (B) 
Immunoblot analysis of dBACs after 8-Br-cAMP stimulation in the presence of DMSO, 
Rapa, Torin, Wrtm., or H89 for the indicated antibodies.  (C) Immunoblot analysis of BAT 
from wild type mice after NE stimulation for the indicated antibodies.  (D) Immunoblot 
analysis of BAT from mice that were either housed at 22°C or 4°C for 2h for the indicated 
antibodies.   
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result corroborates our findings obtained in dBACs that PKA might be a novel 
upstream regulator of mTORC1.  Future studies should be aimed at 
identifying the molecular mechanism through which PKA signaling affects 
mTORC1 activity.  It is well known that the TSC complex, a negative 
upstream regulator of mTORC1 signaling, is a crucial signaling hub through 
which many pathways impinge on mTORC1.  For example, AMPK, Erk 
(MAPK pathway), GSK-3β (Wnt signaling), and Akt (PI3K signaling) 
phosphorylate TSC2 at various sites to either activate or inhibit the TSC 
complex, which subsequently affects mTORC1 activity (Dan et al. 2002, 
Manning et al. 2002, Potter et al. 2002, Corradetti et al. 2004, Inoki et al. 
2006, Ma et al. 2007).  Thus, PKA signaling could potentially phosphorylate 
TSC2 and thereby inhibit the TSC complex, which leads to activation of 
mTORC1.  Analysis of TSC2 phosphorylation sites by Mass Spectrometry in 
dBACs upon cAMP stimulation in the presence and absence of PKA inhibition 
could for example reveal potential regulatory phosphorylation sites on TSC2 
that are affected by PKA signaling upon β-adrenergic stimulation.  Taken 
together, our findings demonstrate that both mTORC1 and mTORC2 are 
activated upon β-adrenergic stimulation in brown adipocytes, however through 
different mechanisms (Figure 2). 
 
 
Figure 2.  Schematic overview of how β-adrenergic signaling 
affects mTORC1 and mTORC2 in BAT.  For details see text.   
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Since we observed increased mTORC2 signaling in BAT with cold 
exposure, we hypothesized that mTORC2 in BAT affects NST.  Indeed, we 
found that AdRiKO mice were hypothermic and sensitive to cold stress, 
suggesting that mTORC2 signaling in adipose tissue is an important regulator 
of temperature homeostasis.  While AdRiKO mice did not display any defects 
in the induction of lipid mobilization, oxidative metabolism and mitochondrial 
uncoupling in BAT upon cold exposure, AdRiKO mice showed a strong 
impairment in cold-induced glucose uptake and glycolysis. Induction of 
glucose metabolism in BAT upon cold exposure is a critical process to 
maintain cellular ATP levels, since mitochondrial ATP production is reduced 
due to activation of UCP1 and subsequent uncoupling (Lindberg et al. 1967, 
De Meis et al. 2012).  Importantly, restoration of glucose metabolism by 
overexpression of hexokinase II in BAT of AdRiKO mice was sufficient to 
restore basal body temperature and improve cold tolerance.  Collectively, 
these data highlight the important role of BAT glucose metabolism in 
organismal temperature regulation.  Moreover, our findings suggest that 
mTORC2 in BAT regulates temperature homeostasis by stimulating glucose 
metabolism when mitochondria are uncoupled to maintain energy 
homeostasis. 
Interestingly, a recent study by Olsen et al. found that mTORC2 is 
required for β-adrenergic-induced glucose uptake in brown adipocytes in vitro 
(Olsen et al. 2014).  Olsen et al. proposed that mTORC2 regulates this 
process by stimulating GLUT1 translocation to the plasma membrane 
independently of Akt (Olsen et al. 2014).  In contrast to this, we could not 
observe any defect in GLUT1 plasma membrane localization in BAT of 
AdRiKO mice. Hence, mTORC2 might regulate glucose uptake and glycolysis 
via different mechanisms in vivo and in vitro.  How does mTORC2 regulate 
cold-induced glucose uptake and glycolysis in vivo?  Our data suggest that 
mTORC2 stimulates glucose uptake and glycolysis in BAT via its downstream 
target Akt, since over-expression of a constitutively active version of Akt2 
(Akt2S474D) in BAT of AdRiKO mice restored cold-induced glucose uptake, 
body temperature and improved cold tolerance in these mice.  These data 
demonstrate that in analogy with insulin-mediated glucose uptake, also β-
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adrenergic stimulation-induced glucose uptake is dependent on PI3K-
mTORC2-Akt signaling in BAT in vivo.  It is well established that Akt mediates 
insulin-induced stimulation of glucose uptake via translocation of GLUT4 to 
the plasma membrane (Kumar et al. 2010).  However, in analogy to our 
findings regarding GLUT1, we could not observe any defect in GLUT4 plasma 
membrane localization in BAT of cold-exposed AdRiKO mice.  Hence, our 
data suggests that translocation of glucose transporters to the plasma 
membrane is not likely to mediate cold-induced glucose uptake via Akt in BAT 
in vivo.  Interestingly, we detected an induction of cytosolic hexokinase activity 
in BAT of control mice upon cold exposure, which could account for the cold-
induced increase in glucose uptake and glycolysis in BAT.  It has been 
proposed that mitochondria-associated hexokinase uses ATP generated in 
the mitochondria to phosphorylate glucose (Wilson 2003).  However, upon 
cold exposure, mitochondrial ATP production is strongly reduced in BAT due 
to activation of UCP1 (Lindberg et al. 1967, De Meis et al. 2012).  Thus, our 
data suggests that induction of cytosolic hexokinase activity might mediate the 
increase in glucose uptake and glycolysis with cold exposure in BAT.  
Interestingly, AdRiKO mice displayed a defect in the induction of cytosolic, but 
not mitochondrial, hexokinase activity with cold exposure.  mTORC2 signaling 
is thus required for induction of cytosolic hexokinase activity with cold 
exposure. How does mTORC2 in BAT affect cytosolic hexokinase activity?   
Hexokinase II is a known target of Akt (Gottlob et al. 2001, Miyamoto et al. 
2008). Thus, mTORC2 might regulate cytosolic hexokinase via its 
downstream target Akt.  Interestingly, a recent publication by Betz et al. (Betz 
et al. 2013) demonstrated that insulin stimulation leads to mTORC2-Akt-
mediated phosphorylation of hexokinase II at T473, which in turn results in the 
translocation of hexokinase II from the cytosol to the mitochondria.  However, 
in contrast to Betz et al., we did not observe any changes in subcellular 
localization of hexokinase II upon cold exposure.  Nevertheless, the Akt-
mediated phosphorylation of hexokinase II might still regulate induction of 
cytosolic hexokinase II activity in BAT upon cold exposure.  Future 
experiments should be performed to address this possibility.  Furthermore, 
even though only the hexokinase II isoform is known to contain an Akt 
phosphorylation motif, also other hexokinase isoforms could potentially be 
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involved in cold-induced activation of cytosolic hexokinase activity.  This 
possibility could be investigated with immunoprecipitation experiments using 
an Akt-phospho substrate antibody followed by immunoblotting for different 
hexokinase isoforms.  Moreover, Mass Spectrometry analysis of the 
immunoprecipitates could furthermore reveal the precise hexokinase 
phosphorylation site(s) that are potentially phosphorylated by Akt in BAT upon 
cold exposure.  Subsequent generation and analysis of phospho-mimetic or -
deficient hexokinase mutants in vitro and in vivo could then be used to 
determine the role of these potential Akt phosphorylation sites regarding 
induction of glucose metabolism upon cold exposure. 
As mentioned earlier, we also found that mTORC1 is activated upon 
NE stimulation and cold exposure in BAT in vivo (Figures 1C and 1D).  Thus, 
it would be interesting to investigate in future studies the significance of 
mTORC1 induction in BAT upon cold stress for NST.  Interestingly, adipose 
tissue specific raptor KO (AdRaKO) mice display a browning phenotype of 
WAT, while UCP1 expression is unaltered in BAT (Polak et al. 2008).  
However, the response of AdRaKO mice to cold exposure has not yet been 
tested.  Thus, to investigate this, AdRaKO mice could be exposed to 4°C and 
their body temperature, energy expenditure and gene expression profile in 
BAT could be determined. Based on the current knowledge it could be that 
AdRaKO mice display an improved cold tolerance due to an enhanced 
thermogenic capacity in WAT.  However, since we found that mTORC1 
signaling is induced in BAT upon β-adrenergic stimulation, it could be that 
UCP1 induction in BAT upon cold exposure is impaired in AdRaKO mice, 
resulting in an impaired thermogenic response. 
 
Taken together, the two studies presented in this thesis describe novel 
functions of hypothalamic and adipose mTOR signaling in the regulation of 
systemic energy homeostasis.  Surprisingly, we found that mTORC1 signaling 
in Agrp neurons is dispensable for the regulation of food intake and 
organismal energetics.  However, we demonstrate a novel role for mTORC2 
signaling in cold-induced glucose uptake and glycolysis in BAT, which in turn 
is crucial for the regulation of systemic energy homeostasis upon cold stress.  
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Our results could thus be important for the development of novel therapies to 
treat metabolic disorders, such as diabetes and obesity.  In particular, our 
findings imply that the use of mTOR inhibitors as an anti-obesity and anti-
diabetic treatment could have potential caveats due to the impact of mTORC2 
in BAT on temperature homeostasis and glucose metabolism.  Moreover, our 
study suggests that glucose metabolism in BAT plays a major role for the 
maintenance of energy homeostasis under NST.  Our data suggest that 
activation mTORC2 in BAT, to stimulate glucose metabolism, could have 
synergistic effects with NST activators in the treatment of obesity. 
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